In the Cup of Trembling, I wrote about who waits and who chooses, and about a pearl buried under the foundation of the house. This post is about the thing the entire house is built toward, and the word for it is one I have used before on this board and have come back to because nothing else fits. Convergence. Not a coincidence of events. A set of separate roads that always were, if you trace them far enough, headed for the same intersection.

Before I show you how the roads converge, I want to ask the question underneath all of it, because the answer is the compass for everything which follows. What is pharmacotherapy actually for? Why do drugs exist, and why does the system approve the ones it approves?

What a drug is for, and why that question decides everything

Strip away the stock, the partners, the tape, and what is left? A drug exists for one reason: to change the course of a disease in a human being who would otherwise suffer it. That is the entire purpose. Everything else, the trials, the endpoints, the approvals, is machinery built to help us answer one question with sufficient certainty to act upon: does this thing actually help a person, and is it safe enough to be worth it.

That is not my framing. It is the law. To approve a drug, the FDA requires what the Food, Drug, and Cosmetic Act calls substantial evidence of effectiveness, drawn from adequate and well-controlled investigations, weighed against safety. (FDA, providing clinical evidence of effectiveness) The system was built, deliberately, to be unmoved by any mechanism which sounds good, by stories, or by conviction. It wants proof that the path of disease bent. In recent years the agency has even formalized a path where a single convincing trial plus confirmatory evidence would suffice, which lowers the number of trials but not the standard of proof.

Keep that, because it is the discipline which makes convergence meaningful rather than wishful. Convergence only counts if the roads converge on that, on proof that a disease is bent in a human being. A dozen roads which converge on a nice idea converge on nothing. So as I lay out the roads, watch where they together meet, and watch whether they meet at the one place the law says actually matters.

Road one: the molecule was never built for one disease

Two years ago I wrote that leronlimab would lift the response rate in colorectal cancer, and I graded that post plainly in my last writeup, right structure, wrong specifics, a number I felt rather than derived. But underneath the specifics which I got wrong, was a structure I got right, and it is the first road. Leronlimab blocks CCR5, and CCR5 is not a colorectal receptor. It is a chemokine receptor that the published literature places at a crossroads the body uses in cancer after cancer, after cancer. The AACR review in Cancer Research surveys CCR5 as a broad oncology target across tumor types, not a single-indication one. (Recent Advances Targeting CCR5 for Cancer, Cancer Research 2019)

https://preview.redd.it/ao3pg17tptuh1.png?width=702&format=png&auto=webp&s=490acf3559c1257b774e8637b43788e3bdb48725

In breast cancer, the published work shows leronlimab blocks metastasis and sharpens the killing done by DNA-damaging chemotherapy. A 2026 review places the CCR5-CCL5 axis upstream in pancreatic cancer alongside the other lethal solid tumors, naming leronlimab's translational potential directly.

So the first road is the molecule itself. The literature describes a multi-use key, not a single-door tool. That is road one, and it is laid down in the journals long before any of us arrived.

Road two: the history of what happens when a key is recognized

The second road is not biology, it is precedent, and it is the reason the first road matters commercially rather than only scientifically. There is a documented pattern in modern medicine for what happens to a drug the day the field stops seeing one disease and starts seeing a mechanism which spans many.

Pembrolizumab, Keytruda, was approved in September 2014 for one thing, advanced melanoma that had failed other therapy. (Merck, first FDA approval of KEYTRUDA, 2014) It was not a melanoma drug any more than CCR5 is a colorectal receptor; it released a brake the immune system puts on itself, and that brake is universal. In May 2017 the FDA approved it for any solid tumor carrying a molecular signature regardless of where the tumor sat, the first tissue-agnostic approval in history, the day the field officially stopped seeing a disease and started seeing a key. Keytruda now carries roughly forty indications and is the best-selling drug on earth. The molecule never changed. The recognition changed, and the value lagged the recognition.

Road two is the map of road one's destination. It tells us what a recognized platform is worth, and it tells us the recognition is earned at a specific place: the first confirming clinical proof, then the second that shows the key fits a distant lock.

Road three: the trial that turns the key, in the open, right now

The third road is CLOVER, and this is where the two abstract roads touch ground. CLOVER is the first door, metastatic colorectal cancer, the setting where the response rate either proves the key turns or does not. CytoDyn presents updated CLOVER data as poster 820P at ESMO on October 25, presented by Dr. Benjamin Weinberg of Georgetown, with the abstract released October 19. (CytoDyn to present CLOVER data at ESMO 2026) That is the sound of the key going into the lock. ASCO GI in January, the confirmed response rate, is whether it turns.

And behind that first door, the other doors are being cut in the open, which is the part that makes this convergence not a single bet. The pre-I-SPY platform was amended to pan-solid-tumor. The CHAMP study takes a liver biopsy. The breast program carries the pooled survival signal that a 2026 review summarized as median progression-free survival around 6.1 months and overall survival beyond twelve, with the longest follow-ups past thirty-six months in some cases. Those are some of the other locks, pre-cut, waiting to see whether the key which turns in colorectal is the universal, master key the CCR5 literature says it should be.

Where the roads meet

Now stand back and look at the intersection, because this is the whole post.

Road one says the molecule is a key, in the journals. Road two says a recognized key is repriced like a city, in the regulatory record. Road three says the proof that converts the key from recognized to demonstrated is being generated right now, on a schedule, in the open. And underneath all three sits the question I opened with: a drug exists to bend a disease in a human, and the law approves it only on proof that it did. That is the intersection. Every road in this story is converging on a single confirmed clinical result, because that result is the only thing which satisfies all three roads at once. It proves the molecule bends the disease, which is what the law requires. It delivers the first confirming proof, which is what road two says triggers Platform recognition. And it is the readout road three is built to produce.

This is why I keep coming back to the word convergence. It is not that many good things are happening at once. It is that many separated things, the biology, the precedent, the trial, the regulatory standard, all require and depend upon, the same event to resolve, and that event is weeks and then months away. They have been traveling toward it the whole time.

What this does and does not promise

I graded myself two years ago for writing the best case as the only case, so I will not do it here. Convergence is not a guarantee that the roads actually meet in triumph. It is a statement that they meet, and that the meeting point is a single readout that can go more than just one way.

If CLOVER confirms a response rate that clears the backbone, all three roads arrive together: the molecule is shown to bend the disease, the first lock turns, and every pre-cut door becomes a question of when rather than whether. That is the convergence the literature and the precedent point toward, and it is the outcome I lean to. If the readout is muddy, the roads are still real but the meeting together is delayed, and the market's patience, and the company's, gets tested. And if the response does not come, then the key was not what the journals suggested, and we will have learned that at the one place the law says we must, in proof rather than in hope. A convergence that cannot name that third outcome is not analysis, it is a wish with references.

But here is what the convergence does promise, and it is not small. It promises that this was never a lottery ticket on just one disease. It is a mechanism the literature already recognizes as broad, standing at its first door, with the other doors being cut and waiting, moving toward the single kind of proof that the entire apparatus of medicine, scientific, commercial, and legal, is built to recognize. The market is currently pricing a locksmith with just one uncertain door. The convergence of these roads describes a master key at the moment before the first turn. Those two descriptions cannot both survive over the next few months. One of them resolves, at the intersection, in the direction the data points.

We are weeks from Madrid, and a few months from San Francisco. Everything I have documented for years, and everything this board has built in the stretch since, has been traveling toward that intersection. Let us stand at it clear-eyed, remembering what a drug is for and what the law demands as proof, and let the readout, not any of us, tell us whether the roads arrived.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I hold a position in the company discussed and you should weigh what I write accordingly. This post synthesizes published biology, regulatory standards, the documented history of platform drugs such as pembrolizumab, and the current status of the CLOVER trial; the historical and biological claims are cited to primary and peer-reviewed sources above, which you should read for yourself. The convergence described is a framework for thinking, not a promise of outcome. Leronlimab has not received the confirmatory clinical readout the argument turns on; CLOVER data will be presented at ESMO on October 25, 2026, and the confirmed response rate is expected at ASCO GI in January 2027, neither of which has been reported. The pooled mTNBC survival figures are drawn from a published review of earlier studies and are not a prospective result in colorectal cancer. A mechanism recognized as broad in the literature does not guarantee clinical success in any indication, and drugs that make elegant biological sense fail in trials routinely. This one may. Read the linked sources and reach your own conclusions rather than adopting mine.

If you have followed this story for a while but stepped away for a single week, this past one, you missed the week the whole thing changed character. Not because the treasure was dug up. Because, for the first time, the owner of the property walked out to the road, unrolled the survey, and read it to us line by line. And a few of us who had been arguing about the core samples for years suddenly had the actual document in our hands.

Let me tell you exactly what was on it, because if you already understood the setup, and you did, then this week is the part where the setup starts resolving into something you can no longer wave away.

The house, for anyone who needs the frame

Here is the picture we have used all along. A group of us went in together on a property. The house you can see from the road is fine, ordinary, unremarkable. The reason we bought it is that the surveyors believe something of extraordinary value is buried under the foundation. For years, all anyone on the sidewalk could do was study core samples and argue about what they meant. Skeptics said the samples were noise. We said they pointed at something real. Nobody could settle it, because the treasure was still in the ground.

This week the owner did something he had never done. He posted the survey on the permit board out front and read it aloud. He did not claim the treasure was dug up. He told us precisely what the core samples show, exactly how the digging is scheduled, and exactly when the assay results come back. And the survey, read in full, points in one direction with a clarity the sidewalk arguments never had.

What the survey actually said, page by page

(The images in this post are derived from: Corporate Deck, September 2026)

Page one: the core samples are deeper than we knew, and they get deeper the harder you dig. The molecular readout, the tumor DNA in the blood, now shows a median decline of 86% at just two weeks across the patients measured.

https://preview.redd.it/cjex8wnnbgqh1.png?width=1065&format=png&auto=webp&s=3154a04ab33880692bf4aed9e61112ca10cb07d5

And here is the part that turns a number into a signal: when you split it by how much you dig, the higher dose goes deeper. The 700 mg group dropped 90%; the 350 mg group dropped 80%.

https://preview.redd.it/l51t7wbxbgqh1.png?width=1065&format=png&auto=webp&s=ba660cc06070c8313e62b6a63efee08338d91c2b

A dose that digs harder and finds more is not what you see from a random core sample. It is what you see when there is actually something there responding and yielding to the tool.

Page two: the ground here is harder than the ground the last surveyors worked. This is the detail that reframes everything, and it came straight off the owner's comparison table. The current standard of care in this disease, the tool everyone else uses, produces a real, tumor-shrinking response in about 6.1% of patients, and in the real world closer to 2.7%. (SUNLIGHT, NEJM 2023, cited on slide 18)

https://preview.redd.it/oaj985gjcgqh1.png?width=1064&format=png&auto=webp&s=ee4ced710185e579090a9306182a6f9904e5616e

That is the graveyard our house sits in. But here is what the owner showed on his baseline slide: our patients are sicker than the ones that low bar was measured on. In the benchmark study, only about 2.6% of patients had reached a third line of therapy; in ours, 52.3% had.

https://preview.redd.it/2o5izsspdgqh1.png?width=1064&format=png&auto=webp&s=6e6bf98facef8377e0a83e4099d7daf4f80baf89

We are digging in harder ground, with more exhausted patients, and the core samples are still coming back this deep. That makes the target which the owner named, an ORR meaningfully above that 6.1%, much more impressive, not less, because it would be achieved against a tougher population than the benchmark had ever faced.

Page three: the owner is being scrupulously honest about what is not yet proven, and that honesty is the tell. The same slide that shows 22 of 65 patients still on the study carries a footnote in plain sight: "results are based on a preliminary data cut," and "reported outcomes may change up until database lock." (highlighted footnote above)

Read that carefully, because it matters. A man hiding a weak hand does not label his own best slide "preliminary" and warn you that the numbers may move. A man reading you an honest survey does. This is a surveyor who wants you to trust the assay when it comes back, so he refuses to overstate the core samples now. That discipline is worth more than any single number on the page.

The one place a careful reader must not be fooled, and it is good news

Here is where I owe credit, because the sharpest reading of the survey this week came from the community, not from me. BuildGoodThings did the granular work on how a "response" actually gets counted, and it dissolves the single biggest way a newcomer could misread this.

When the owner showed his most-photographed core sample, the patient labeled 103-001, the slide reports a 97% collapse in tumor DNA and a 21% shrinkage in tumor volume, and then classifies that patient as Stable Disease.

https://preview.redd.it/eb9ziecwegqh1.png?width=1063&format=png&auto=webp&s=478b31e6ea072905e9e9f99cb8fd53b3a4f8351d

A newcomer sees "97% and 21% and shrinking" and expects "responder." The slide says Stable Disease. Why? Because the formal response bar is a 30% shrinkage, confirmed by a second scan. u/BuildGoodThings walked through this using the actual RECIST rulebook: a response is not counted until a later scan proves the shrinkage held. (RECIST v1.1 guidelines, confirmation of response, section 4.4) So 103-001 is not a disappointment. 103-001 is a patient walking toward the response line, caught mid-stride, on the lower dose, with the confirming scan still ahead.

Sit with what that means, because it is the crux of the whole week. The headline response number, the one measured against that 6.1% graveyard, is a figure that builds across scans and matures over time. It is designed to read low early and firm up later. Which means the interim look in October is the appetizer, and the confirmed number in January is the meal. The survey did not just tell us what the core samples show. It told us the good part of the assay is structurally back-loaded toward January, by the rules of measurement themselves. u/rogex2 and u/sunraydoc pressed exactly this point in a discussion, that "22 remaining" is not a body count, it is a snapshot of who is still actively being measured while progressors, curative-surgery departures, and completed patients are accounted for separately. They were right, and the deck's own footnote confirms it.

What the owner is building while we wait

The survey also showed that the owner is not sitting idle while waiting for the dig. He has formally amended the plan, Amendment #6, to let patients who are doing well continue, and to give patients whose disease progresses a salvage path: escalate to the higher dose and to add a checkpoint inhibitor.

https://preview.redd.it/l5717wfyggqh1.png?width=1062&format=png&auto=webp&s=dc19025abd4d881851cc5d5e63558b9cd8f53137

He has a diagnostics partner, Natera, running the molecular assay and supplying a 144,000-patient real-world comparison so the FDA can see exactly what the tool adds on top of the backbone.

https://preview.redd.it/2sc659ojhgqh1.png?width=1062&format=png&auto=webp&s=fb554cb1a0107a961c55493be0a9540b9f3a8501

He has the property funded past both assay dates, so there is no forced sale into the results. And he stated the near-term plan plainly: assemble a data package for the FDA in the second half of this year, and present the maturing data at the two conferences.

https://preview.redd.it/3wc4j9wvhgqh1.png?width=1063&format=png&auto=webp&s=19147e83acca609d2045dca7bec76099ed466ee6

And he named the two dates that end the waiting. The full molecular picture at the European congress, October 23 to 27. The fuller picture, molecular plus response rates plus early survival, at the gastrointestinal cancer meeting, January 20 to 23.

https://preview.redd.it/ngz405l8igqh1.png?width=1063&format=png&auto=webp&s=7dee558cb4ebf3cefeffbf37a23adcc694fa18ab

Two readings. The first matures the survey. The second reads the assay.

Where this leaves the house

So here is the conclusion the week points to, and I state it with the confidence the facts earn and not one inch beyond.

Everything on that survey bends towards the same direction.

• Core samples which deepen with dose.
• A tougher patch of ground than the benchmark was measured on, and the samples still coming back deep.
• An owner labeling his own best slide as "preliminary" because he intends for the assay to speak for itself.
• A response metric that, by the rules of measurement, is built to read modestly now and confirm later, which means the strongest reading is structurally reserved for January.
• And a man building the machinery, the amendment, the partner, the FDA package, of someone who expects to have something worth carrying forward.

No single one of those is proof. But they do not point in scattered directions. They point, together, at one reasonable expectation: that when the assay comes back, it will show more than the graveyard has ever produced.

That is not the same as saying the treasure is certain. It is not dug up. A preliminary core sample is not a certified assay, and the owner said so himself, on the slide, in writing. Beautiful surveys have come back empty before. So hold it exactly where the facts hold it: the survey reads strongly, it reads honestly, and it reads in one direction, and the only thing left is to let the digging finish and the assay return. The uncertainty that remains is not "is there anything there." It is "by how much," and "confirmed to what degree", and those are answered in October and January, not on the permit board.

For anyone who is just walking up to this property: you did not miss the treasure being found. You missed the week the owner stopped letting us argue about the core samples and read us the actual survey, and the survey, read in full and read honestly, is hard to interpret any way but one. The house looks ordinary from the road. The document nailed to the permit board this week says the ground underneath it is not ordinary. We find out how right that is in a matter of weeks.

The survey has been read. The dig is scheduled. The assay comes back in two readings. And the only remaining question is the size of what is down there, not whether the arrow points at it. This week, the arrow got very hard to argue with.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is my interpretation of a public investor slide deck, a public trial registry, and community discussion, not a prediction of clinical, regulatory, or commercial outcomes, and not a claim that any endpoint, designation, approval, or partnership will occur. The CLOVER figures are explicitly labeled by the company as a preliminary data cut subject to change until database lock; the primary confirmed objective response rate is unreported. ctDNA, disease-control, and PD-L1 figures are interim, reflect combination therapy with a chemotherapy backbone, and are not evidence of a survival benefit. Patient 103-001 is classified as Stable Disease, not a confirmed response. Dose comparisons are early and unconfirmed. "22 of 65 remaining on study" is a snapshot of active participants and does not represent a mortality figure. ctDNA is not a validated surrogate endpoint for approval in colorectal cancer. The company has disclosed substantial financing needs and going-concern considerations in its filings. Interim data is anticipated at ESMO (October 23-27, 2026) and confirmed data at ASCO GI (January 20-23, 2027). Read the primary sources, linked throughout, and reach your own conclusions rather than adopting mine.

https://journey.ct.events/view/bf1c7d07-71f3-4c41-8928-f42479da2d71

00:25 Dr. Lalezari

Thank you to HC Wainwright for the opportunity to present today CytoDyn's exciting new asset, which we think of as the next generation of monoclonal antibody therapy. The talk today will include a number of forward-looking statements, with all that that implies.

00:47

CytoDyn is a clinical-stage oncology company advancing leronlimab, our first-in-class humanized monoclonal antibody, which targets the CCR5 receptor, with therapeutic potential across multiple indications, including a number of solid tumors such as colorectal cancer and triple-negative breast cancer.

01:11

The leadership team includes myself, Robert Hoffman our CFO, and Tyler Block our chief legal officer. It is really the three of us that constitute the management team.

Leronlimab is an IgG4 monoclonal antibody that has already demonstrated multiple mechanisms of action relating to its activity in solid tumor oncology. It is a drug targeting a large and growing market potential, not only CRC and TNBC, but a number of other solid tumors as well. Very importantly, leronlimab has a very well-tolerated safety profile, including more than 1,600 patients across more than 20 studies. We have strong retrospective data in triple-negative breast cancer, which really helped focus the company on solid tumor oncology. And since then we have launched the Phase 2 CLOVER study and have some very exciting early readouts from that study in metastatic colorectal cancer, supporting the proposed mechanisms of action associated with the drug.

02:28

Our near-term milestones include confirming the durability and safety of these efficacy readouts from the CLOVER study in CRC, with a presentation at ESMO in October in Madrid, where we are going to present extensive circulating tumor DNA (ctDNA) data on all 65 subjects, which includes the intent-to-treat population. And then at ASCO GI in January in San Francisco, we will be giving a more fulsome presentation of not only the ctDNA, but also the overall response rates and early progression-free survival.

03:08

https://preview.redd.it/wxihqg0l82ph1.png?width=1600&format=png&auto=webp&s=bb3ab231baf4b7c370348636d3c761a5fe94964a

The CLOVER study in colorectal cancer

Starting with the exciting data being generated in CRC, the study is called CLOVER. It is a Phase 2 study, open-label, randomizing patients to either 350 or 700 milligrams of leronlimab, on a backbone of Lonsurf and Avastin. We targeted 60 patients and ended up with 65 patients dosed. This is our third-line metastatic colorectal cancer population that is microsatellite-stable, and therefore not a population one treats with checkpoint inhibitors. Our lead investigator is Dr. Kasi, our director of GI oncology down at City of Hope, and we fully enrolled the study this past April.

The DSMB (Data Safety Monitoring Board) has met three times, initially to open up the 700-milligram randomization arm, and at two subsequent times. In all three meetings there have been no safety concerns raised.

04:15

https://preview.redd.it/ls0q35aw82ph1.png?width=1600&format=png&auto=webp&s=d39d55a68b01bc97a30d3d846c3e18941361349b

The preliminary results from CLOVER are exciting in a number of ways. First, 100% of our screened patients tested positive for CCR5, and that includes either 10% expression on the tumor epithelial cells or 1% in the lymphocytes in the tumor microenvironment, significantly expanding the potential population of patients who could benefit from leronlimab.

At a minimum, the second bullet point associated with leronlimab has to be its safety profile. It has been well tolerated, even in this study of very advanced and fragile patients. There are no serious adverse events related to leronlimab, and importantly, leronlimab has no dose- or treatment-limiting toxicity, meaning the leronlimab dose does not need to be adjusted for any adverse events. That excellent safety profile continues.

05:18

The ctDNA data

Very excitingly, at AACR in April, we presented our early ctDNA declines in the first patients enrolled through City of Hope, results which were obtained under standard of care. We have since finalized the partnership with Natera, and they are completing ctDNA analysis on the other half of patients, who were enrolled under the research protocol.

05:43

What is exciting is that nearly all the patients showed a decline in ctDNA, even as early as week two, with a median decrease of about 85% across all patients, and an early signal of a dose response, which is important. We are working with Natera to generate a comparative ctDNA data set that we can present to the FDA later this year. In the meantime, showing a dose response further drives home the point that these exceptional declines in tumor DNA are largely being driven by the contribution of leronlimab.

06:23

https://preview.redd.it/x1xamu6692ph1.png?width=1600&format=png&auto=webp&s=95c919f1dd2cbe71ecc20813a32fa8ec2090bc28

These are the data presented in April, the first 19 patients, fairly dramatic DNA declines even at week two in all or the great majority of patients. Importantly, about two-thirds of these individuals have a RAS mutation, so it appears that leronlimab's activity is agnostic to the presence of RAS.

06:58

https://preview.redd.it/ta1r6yma92ph1.png?width=1600&format=png&auto=webp&s=05251e2d0fa906c305a4c9ba469523a24115971f

These were the week-two data, and then these are the first 23 patients, and you can see the trend has continued toward rapid and very significant declines in DNA. Again, we will be generating a comparative data set from the Natera database to compare this activity with the backbone alone.

07:20

https://preview.redd.it/919no27e92ph1.png?width=1600&format=png&auto=webp&s=891f09eb7e8e85f485472d0782ed737f09dd62fb

And if you break down that early readout by dose, you see this very tantalizing suggestion of a dose response, which underscores that this is largely being driven by leronlimab and leronlimab dosing.

07:42

https://preview.redd.it/ke9xndvg92ph1.png?width=1600&format=png&auto=webp&s=d3eb926f0f6e9c4d17cf7f7db4cfd863b12d8742

Scans, PD-L1, and the standalone-versus-prime-and-pair distinction

In concert with these ctDNA declines, we are also reporting that the scans at week eight in the majority, three-quarters, of the patients are demonstrating shrinkage or classify as having stable disease, and we look forward to elaborating on that in the coming weeks and months at both ESMO and ASCO GI.

08:01

Importantly, we are reporting that there are numeric increases in PD-L1 observed in the majority of patients in that CRC study. In CRC, we are really developing leronlimab as a standalone agent to be used in combination with standard of care. In breast cancer, as we will see in a moment, what we have observed is an induction of PD-L1, turning cold tumors hot, and thereby enabling, apparently, the use of a checkpoint inhibitor to create a pathway to sustained remission.

So in CRC it is a standalone leronlimab, and in breast cancer it is more of a prime and pair. But the prime and pair works because of what leronlimab does as a standalone agent, priming the tumor for treatment with the checkpoint inhibitor, by disrupting the tumor microenvironment and allowing the host immune system access to the cancer. It is very exciting that in the CRC study we are also seeing increases in PD-L1. It is difficult to know what those increases will mean in terms of translating into clinical benefit when you add a checkpoint inhibitor, and that is something CytoDyn is about to start looking at. But in the meantime, that signal of increased PD-L1 in patients with CRC is a signal that the tumor is under stress, and that leronlimab's impact on the tumor microenvironment may well be allowing the host immune system access to the cancer, which it otherwise did not have, with the cancer responding by expressing PD-L1, trying to beat back that host immune system.

09:40

Very importantly, speaking to the investigators, they are all excited by what we are seeing in terms of DNA, but in particular they are telling us that patients are doing well clinically. The investigators are writing fewer scripts for pain medication and observing that there are fewer hospitalizations in this rather end-stage population than they anticipated.

10:07

https://preview.redd.it/p7dv3ua422ph1.png?width=1600&format=png&auto=webp&s=e3494850b399fe603595c72ad1104e16eea01cd4

So we are excited about the DNA, and looking forward to reporting on the radiology outcomes and more extensive reports on progression-free and overall survival. Dr. Kasi at City of Hope is our principal investigator, who presented the data at AACR.

10:33

https://preview.redd.it/u3eqes7d22ph1.png?width=1600&format=png&auto=webp&s=5021a3056bf41bd920d8058df4a9d7029737abfb

The first-patient case study

In addition, Dr. Kasi, on the next slide, observed the first patient he enrolled, who had a rapid decrease over two weeks, something he had not seen before in an end-stage patient with metastatic CRC. That patient's ctDNA level went from about 129,000 parts per million down to about 10,000 parts per million.

11:00

https://preview.redd.it/6abl9ppk22ph1.png?width=1600&format=png&auto=webp&s=dfe370f82aa6a0d557d1943740ac841a1294ddb1

And then what he saw on the following two scans, first in the liver, the baseline scan on the left and the week-8 scan on the right, this is in a patient who had a 97% decrease in ctDNA, you can see that the tumor volume decreased approximately 21% from baseline to week eight. And indeed, not only does the tumor get smaller, but it appears to become more translucent.

11:25

https://preview.redd.it/w308mjcq22ph1.png?width=1600&format=png&auto=webp&s=8897480e83dab4cb24fff2ecc459b8f2d73b9283

This is even more pronounced on the next slide, which is that same patient with lung metastasis, and you do not have to be a radiologist to appreciate the impact, the shrinkage of that tumor from baseline to week eight after starting leronlimab.

11:40

https://preview.redd.it/54yjnnfv22ph1.png?width=1600&format=png&auto=webp&s=2f5dc114168b39d09b473d38c068a3dbb241aab9

In addition, Dr. Kasi has performed liver biopsies on a number of patients, and we will be launching a study to really interrogate biopsy tissue from these patients treated with leronlimab, to tease out the effect the drug is having specifically on the tumor and the tumor environment. In the meantime, for this first patient, I think you can appreciate the slide on the left is with the PD-L1 stain, the slide on the right is similarly stained, and there is a significant impact on the tumor architecture. But what again is very exciting is the CPS score, the combined positivity score of PD-L1 expression on the tumor and tumor microenvironment, at baseline it was 1%, but in follow-up around week 14 it is up to 5%. And again, I think that indicates a tumor under duress, and CytoDyn is taking next steps to launch a study to explore the efficacy of a checkpoint inhibitor in these MSS CRC patients, for whom otherwise checkpoint inhibitors are not indicated. So, very exciting.

12:47

https://preview.redd.it/flcgg15732ph1.png?width=1600&format=png&auto=webp&s=2b221e539adc6ab873e82713eed9ee1ebb427a82

The SUNLIGHT benchmark and the protocol amendment

And then the CLOVER study itself is looking to improve upon the current standard of care, which includes Lonsurf and Avastin, where the overall response rate reported in the Phase 3 SUNLIGHT study, in the New England Journal, indicated 6% of patients with a partial response, meaning a 30% decrease in tumor diameter, and there were no complete responders. More recent real-world data has been presented on a larger cohort of patients, indicating the overall response rate is just under 3%. So we very much look forward to presenting our overall response rate and demonstrating some improvement over the current standard of care.

13:29

https://preview.redd.it/88f6418i32ph1.png?width=1600&format=png&auto=webp&s=3e57278652f053145fa831fd0c1bf79090df2db5

With the CLOVER study continuing, we have amended the protocol such that patients who are doing well after 48 weeks can continue on treatment on their randomized treatment assignment. We also will be initiating very shortly a rollover arm, as salvage therapy, for patients who have documented progression, wherein they will increase their leronlimab dose up to 700 milligrams if they are not already there, and then add pembrolizumab as well.

Additional colorectal studies: CHAMP, CLIOS, and pre-I-SPY

There are a number of other studies in CRC coming. There is an investigator-initiated trial down at City of Hope, Dr. Kasi, in patients with metastatic CRC and multiple liver metastases, who will be receiving a hepatic artery pump and receiving floxuridine through that, in advance of hopefully curative surgery down the road. What Dr. Kasi is doing here is introducing leronlimab in an earlier line of treatment in patients with CRC. This is a project jointly funded in partnership with City of Hope. And Dr. Kasi is leveraging both the anti-tumor effects of leronlimab as well as the liver-protective, or anti-fibrotic, effects, which CytoDyn has published on from a number of both clinical and preclinical studies we previously performed. And then there are 13 different ctDNA timepoints from the 30 or so patients to be enrolled in what is called the CHAMP study. And we are excited to be able to then also look at some ctDNA results from patients on leronlimab monotherapy.

In addition, we have other studies coming in CRC, including a thorough investigation of tumor tissue from patients who were treated with leronlimab. And as well, there is a newly formed network called CLIOS that has reached out and wants to consider studies of leronlimab, both in the neoadjuvant setting as well as in the molecular residual disease setting. And then finally, we are working with the pre-I-SPY network in CRC to launch a study of leronlimab and a checkpoint inhibitor. So a lot of activity in CRC. And again, the main focus is leronlimab as a standalone.

Triple-negative breast cancer: the retrospective data

16:05

https://preview.redd.it/l3uu6xn842ph1.png?width=1600&format=png&auto=webp&s=a3e5b80d0e58085dad09221841af94e091cd3e9b

Then, turning to triple-negative breast cancer. Again, this is where we got the first signal of the potential of leronlimab in solid tumor oncology. There were three studies launched in 2020 that enrolled a total of 28 patients with triple-negative breast cancer.

16:15

https://preview.redd.it/p884pmzc42ph1.png?width=1600&format=png&auto=webp&s=36c780abd6e3b8e798022bfc76fdaccd21e0a4cb

These patients had terribly advanced disease, with two prior lines of therapy in the metastatic setting. Two-thirds had visceral metastases, one-quarter had brain metastases. So this is a population whose survival, unfortunately, is very limited.

16:35

https://preview.redd.it/er7mi5ii42ph1.png?width=1600&format=png&auto=webp&s=481451f7ecb0468483ae760dd5ba43349f6d5cc5

And then what we found, when I came on, was that we wanted to publish the outcome of those studies, so we made phone calls and found out that there were actually 5 of the 28 patients who were still alive. We then went and obtained medical records to determine which patients did well on what treatment. And this slide summarizes that outcome. The seven patients on the right, there is no follow-up blood, so we do not have anything further to say about their outcome and correlation with treatment; this was in the middle of COVID and during lockdown.

For the 21 patients on the left, their blue bars are the baseline measurement of PD-L1 on circulating tumor cells. PD-L1 is commonly understood to be something one measures on tumor tissue or the tumor microenvironment. The lab, Creatv MicroTech in New Jersey, has developed technology to use a fluorescent assay to measure PD-L1 on circulating tumor cells, and in particular the cancer-associated macrophage-like cells that break off from the tumor and enter the circulation. So the blue bars are the baseline. The negative control for that assay is about 175 RFUs, and so anything above 400 is considered to be clinically relevant. And you can see that the majority of patients actually did increase their PD-L1 expression after 30 to 60 days, above that 400 threshold, indicating that the tumor has gone from cold to hot, from a tumor that is typically not responsive to checkpoint inhibitors to one that might be.

Then in the 7 patients in the red box, among these patients on the left: patient number 4 received a low dose of leronlimab and did not induce PD-L1. Patient 5 received 525 milligrams of leronlimab but likewise did not induce PD-L1. The five patients on the right, in the box, all five received either 525 or 700 milligrams. They all induced PD-L1 within that one-to-two-month time frame. They all received the checkpoint inhibitor either with or after leronlimab, and two of these patients had already previously failed a checkpoint inhibitor. And all five of them are alive today, five-plus years later, which I think is an extraordinary observation, albeit retrospective, and just not an outcome that I believe occurred by chance. Of these five patients who are still alive, three of the five are currently documented to have no evidence of disease, and two of those three started with lung metastasis, and one of those individuals started with both brain and lung metastasis, and we recently published our case report.

19:30

https://preview.redd.it/bwb7e4on52ph1.png?width=1600&format=png&auto=webp&s=4e1b02b7136bdbbb6e672d1df8f6cd071194ad4d

In summary from the retrospective TNBC data: there is a 98% reduction in metastasis when you use a CCR5 inhibitor in a preclinical study. Our retrospective clinical data show a reduction in circulating tumor cells in the majority of patients after the first dose of leronlimab, which is very reminiscent of the data we are seeing in colon cancer with the decrease in circulating DNA. We are observing, retrospectively, an upregulation of PD-L1 on about 90% of patients' circulating tumor cells who received either the 525- or 700-milligram dose. And as I said, five out of five of the patients who upregulated PD-L1 and received a checkpoint inhibitor are alive today, five-plus years later. And unfortunately the converse is also true, that 100% of the patients who either did not upregulate PD-L1 or did not receive a checkpoint inhibitor are, unfortunately, deceased.

Based on this retrospective data, we have heard from a number of potential partners that they want to see prospective data confirming this upregulation of PD-L1, and eventually the benefit of adding a checkpoint inhibitor.

20:50

https://preview.redd.it/1ylboovz52ph1.png?width=1600&format=png&auto=webp&s=e299e5c5a38ad443162c2a7ba436a2465906e814

The breast cancer clinical plan

On the clinical plan in breast cancer: first, we are working with the Pre-I-SPY network in patients with metastatic TNBC, doing a dose-escalation study, looking prospectively at ctDNA and PD-L1. We are thrilled to have Dr. Paula Pohlmann serve as our principal investigator. When the first cohort of that is done, we will be looking to design a part 2 of the study, which will examine the contribution of components with a checkpoint inhibitor, and that will be an adaptive study design in up to 120 patients. As well, when the first cohort with metastatic TNBC is done, the I-SPY network has indicated they want to launch a study of neoadjuvant leronlimab in patients with newly diagnosed HER2-negative breast cancer, again significantly expanding the potential population to benefit from leronlimab. Their proposal is to look at a month of leronlimab monotherapy in these newly diagnosed patients in advance of their hopefully curative surgery. I think that makes sense as we move leronlimab up into an earlier line of therapy, because we are seeing very potent anti-tumor activity in a number of solid tumors, and the safety profile of leronlimab suggests it deserves an earlier line of treatment.

Upcoming milestones and priorities

To highlight upcoming milestones in the near and mid term:

22:35

https://preview.redd.it/74pze0mk62ph1.png?width=1600&format=png&auto=webp&s=7610b267ab69e2c15b013e9da0cc4921b019813b

First and foremost, we are confirming the standalone benefit of leronlimab plus the backbone in CRC, both through biomarker collection, the disease control rate, and then the primary endpoint of overall response rate, as well as the crucial progression-free and overall survival.

Second, as we have heard from a number of partner discussions, we need to prospectively demonstrate the induction of PD-L1 in triple-negative breast cancer, where we know that is a critical marker of benefit and is used for the approval of checkpoint inhibitors. We are seeing it prospectively in colorectal cancer, in microsatellite-stable colon cancer, where checkpoint inhibitors are not part of the conversation, but CytoDyn is keen to see if these increases in PD-L1 provide the opportunity to use a checkpoint inhibitor. In the 95% of patients with colon cancer where checkpoints are not indicated, we are prospectively hoping to demonstrate the clinical benefit of adding a checkpoint inhibitor in these PD-L1-induced patients.

And very importantly, to identify the optimal dose in solid tumor oncology. The earliest signals from the CRC study suggest that the 700-milligram dose might be better than 350, and at some point we are going to have to sort out whether there is a difference between 525 and 700.

24:15

https://preview.redd.it/a16776tz62ph1.png?width=1600&format=png&auto=webp&s=9f525bd03a465ff9ce48fb725c316c58cfc4e5d6

Recent and upcoming milestones: we recently closed on $17-and-change million in funding. At the AACR meeting, we presented the initial ctDNA readouts in the CRC study. Those readouts generated a lot of excitement, and CytoDyn is now pursuing collaborations with the Mayo Clinic, MD Anderson, City of Hope, and a number of other major academic cancer centers. We are very pleased to have closed our strategic partnership with Natera, who is both running the Signatera ctDNA assay on our clinical subjects and providing that crucial comparative data set that we can use to help the FDA put our DNA data into context. There is the City of Hope investigator-initiated study called CHAMP, which will initiate shortly, as well as the Pre-I-SPY study in patients with metastatic TNBC. Both of those studies should be initiating in the next 4 to 8 weeks.

I am looking forward to the presentation at ESMO in Spain, which will focus on a complete ctDNA data set for the entire enrolled population, and then at ASCO GI, tying the biomarker data with the radiologic outcomes and early progression-free survival. And there are a number of other additional studies in CRC, including interrogation of whether adding a checkpoint inhibitor to leronlimab, in patients who produce PD-L1, provides an avenue for treatment with a checkpoint inhibitor in CRC, and then studies both in the neoadjuvant setting and in patients with molecular residual disease.

FDA and partnerships

In terms of the FDA and potential partnerships: partners have been wanting to see data as monotherapy, and they wanted to see prospective data. So we are confirming the durability of these exciting safety and efficacy readouts from the Phase 2 CLOVER study. We will be presenting the biomarker data and early clinical data at ESMO, and we plan on putting together a package for the FDA and submitting that for Breakthrough Designation before the end of the year. We are presenting the updated biomarker and more extensive clinical data at ASCO GI, and throughout, a top priority for CytoDyn is our continued evaluation of strategic partnership opportunities.

With that, thank you again for the opportunity to present. I think these data are tremendously exciting. It is important to remember that targeting the CCR5 mechanism and showing proof of concept in colorectal cancer is not only important for CRC, but that the CCR5 mechanism is relevant to a lot of other solid tumors: pancreas, prostate, glioblastoma, kidney, urothelial tumors, and of course breast. And so having proof of concept in a solid tumor such as CRC means a little bit more to a company like CytoDyn, where what remains is the potential to have an impact on quite a few other solid tumors.

Thank you so much Jay.

Every saga worth telling seems to have a similar shape. Something of substantial value, discovered early on. A long, wide and winding wilderness inside of which very few actually believe and understand. A near-death experience as a result of which, the story should have abruptly ended but did not. And then, after years of extreme toil, a reckoning arrives, a single stretch of pathway where the entire journey is finally put to the test, and the wayward wandering either arrives to the destination or it doesn't. CytoDyn stands at the mouth of that stretch of road right now. So on this Labor Day, instead of yet another single argument, let's tackle this saga, gather together what this past week taught us into the story, and conclude as to why the quiet we sense surrounding us is the quiet before the reckoning, and that it is not the quiet of something ending.

The Pearl of Great Price, and the Wilderness It Traverses

The something of substantial value discovered early on, is a molecule that does something almost nothing else in oncology is able to do. Most cancer treatment is a blunt and dull instrument; chemotherapy floods the entire body systemically, not locally specifically directed, with poison and we gratuitously accept the ensuing and inevitable collateral damage because for decades, there was no other way; we endure its indiscriminate action on our healthy tissue and it is exactly that which causes the very suffering patients succumb to. (Chemotherapy's indiscriminate collateral damage, bioRxiv, 2024) Leronlimab is not that at all. It does not poison. In fact, it has a laughable adverse side effect profile. Leronlimab accurately aims, at one, single ancient conversation that a tumor has with the body around it, which is the CCR5 signaling that a cold tumor uses in order to corrupt its own surroundings, the TME and by which, it constructs a stromal wall which the tumor hides within. Therefore, leronlimab passively disarms the tumor's fortress instead of torching the entire village.

The wilderness is the course CytoDyn walked carrying this very molecule unto its destination.

• A clinical hold.
• Years written off by nearly everyone aside for a very few select.
• A stock left for dead, by the vast majority.
• A company so many declared finished that its own believers grew accustomed to being mocked for remaining.

That is the wandering, but each step, was a step up upon a circling, spiral staircase, onward and upward, some times two steps up, and one step down, but yet upward, because the molecule never faltered. And back to the saga, because it is that since the molecule survived it, so did the company's conviction, and today, we've arrived, at last, at the mouth of the narrow gate, where there is data instead of only our unfaltering faith.

The Captain Who Returned

Each and every saga needs a certain leader who steadies the ship, especially at the darkest hour, and this one is real, not invented. Jacob Lalezari MD, has worked with and believed in this molecule for the better part of two decades. He returned to steer the company through the stretch of road it is on right now, guiding and directing to where we stand today, and his posture is the opposite of the reckless era which nearly sank it.

• He does not overpromise.
• He insists on data no one, (FDA included), can argue with.
• He said it himself, that he no longer has to spend his time convincing anyone, he just shows them the numbers, and that has been a pleasure of the job.

That is not the voice of a captain who shouts into a storm. No, he is very relaxed and very confident. It is the voice of one who reads the instruments, who plots the course, and who refuses to firewall the throttle until the runway lights turn green. The steadiness he endows, which frustrates the impatient, is precisely the steadiness a ship requires to cross through the Verrazzano - Narrows.

The Adversary is not who you might think

In this saga, I won't tempt you to cast a villain because the real antagonist in this story is not a company or even a person. It is the disease itself.

Microsatellite-stable colorectal cancer is the fortress that needs to be defeated. In the setting that CLOVER fights, the current standard of care produces a meaningful tumor response in roughly only 6% of patients, and closer to just 3% in the real world. That is the graveyard we're up against. That is the wall a hundred and one approaches have broken against. And this week we were reminded, hard, of just how unforgiving that very wall is. A KRAS-targeted combination, adagrasib plus cetuximab, earned accelerated approval AA in this very disease on a striking single-arm response rate, tumors shrinking at triple the rate of chemo, and then its confirmatory trial showed that the radiographic shrinkage bought no more additional survival, median PFS of only 7.5 months against chemotherapy's 8.1, and the approval is being withdrawn. (Adagrasib confirmatory trial failed to beat chemotherapy, Fierce Pharma, 2026) twinter brought that case to the board, and it is the sharpest possible teacher: the fortress does not fall to tumors merely shrinking on a CT or MRI scan. It falls only when tumors shrink and only when the patients with the shrunken tumors live longer. The adversary is the disease, and the disease has beaten glittering results before. Therefore, either respect it, or you be humbled.

And here is what makes the fortress so stubborn, and why leronlimab is a different kind of weapon against it. A systematic review this month catalogued exactly how microsatellite-stable colorectal cancer stays cold: suppressive myeloid cells, macrophages turned traitor, fibroblasts building a stromal wall, T-cells stranded at the margin unable to reach the tumor core. (Heating the Cold: overcoming immunotherapy resistance in MSS CRC, Molecules, 2026) Read that list and you are reading the exact locks leronlimab is cut to open. And notice the distinction which matters: nearly every other weapon in oncology, chemotherapy, the ADC, the checkpoint inhibitor, the radiopharmaceutical, is a way of delivering or unleashing a killing blow to the tumor cell. Leronlimab is the one that is not a killer. It changes the terrain such that every other weapon lands better. That is why it is not just another item on the fortress's long list of failed siege engines. It is the thing that clears & prepares the ground for the siege itself.

The Weapon, and the Science Validating It

But the weapon we wield is not a lone blade. It is a mechanism which the deeper science continues to confirm is real, from various directions which have nothing to do with each other. That is exactly what actually happens when a target is a genuine one rather than an illusion.

This week alone the same CCR5-CCL5 conversation surfaced in room after room.

• In the aging body, worn-out and exhausted immune cells were shown to flood the bone marrow through the CCL5/RANTES signal, tilting the NLR body's blood factory ratio toward inflammation, but by blocking the CCR5 receptor, the tilt was reversed in aged animals. (CCL5-CCR5 drives age-associated myeloid skewing, Nature Aging, 2026)
• And the stromal TME, the microenvironment, the very fortress leronlimab is built to passively dismantle, was shown yet again to be exactly what shields tumors from conventional chemotherapy and drives their resistance to the blunt instrument. (The tumor microenvironment shields tumors from chemotherapy, PMC)

Different diseases, one conversation. That breadth is far broader than just this, and this is not a coincidence to marvel at. It is the signature of this weapon that is aimed specifically at something ancient and shared.

And the way the weapon is meant to be used grew richer this week as well. The established plan is Prime and Pair: leronlimab primes a cold tumor, dismantles its stromal wall and forces it to raise its surrender-flag called PD-L1, and then a checkpoint inhibitor pairs, by striking that flag such that the now freed immune system can finish off the tumor. That pairing is in trial now, unproven, being tested in the CLOVER rollover. But we also explored a new possibility, a hypothesis, mine, not a trial: that leronlimab could pair with a Trop-2 antibody-drug conjugate like Trodelvy, which is itself chemotherapy that learned to aim, a guided missile carrying an SN-38 payload directly to tumor cells. (Trodelvy is a Trop-2-directed ADC with an SN-38 chemotherapy payload, Gilead) Leronlimab thins the wall, the passive prime; the ADC's aimed payload now has access and invades. u/sunraydoc2 saw the parallel before he read it and offered names for it. One weapon that clears the fortress, another that lands the blow, that is the shape of the next decade if the players engage it and the mechanism proves out.

There is a reason why this priming matters which only became clear this week. A checkpoint inhibitor brings T-cells to the tumor, but it cannot force a cold tumor to raise the very flag the inhibitor is built to strike, because many cold tumors have gone partly deaf to the immune system's signals, as they're ears seem only to be tuned to the hypnotic hum of RANTES. Leronlimab works upstream of that selected deafness, reversing it and in doing so, remodeling the environment and the macrophages themselves, as they emerge out of their zombie, tumor slave state, which is why it is able to raise the flag where as the checkpoint inhibitor alone cannot. And there is a quiet structural advantage in how it does its work: because leronlimab carries no poison, no cytotoxic payload to leak into the blood, it cannot inflict the collateral damage that even the "aimed" chemotherapies and the ADCs still cause. Its remarkable safety is not a lucky accident. It is a direct consequence of being a naked antibody that removes a signal rather than delivering a toxin.

The Ally, and the Gate It Guards

Every saga also has a powerful gatekeeper whose judgment decides whether the journey ends in triumph or exile, and for us, that gate is the FDA, and the truth is that the gate is neither friend nor foe. It is a standard.

This week the gate opened a little wider in a way worth noting, u/Ibelieveincydy flagged it and got out of bed early to do so. The FDA granted accelerated approval AA to a breast cancer therapy guided, for the first time, by detecting a resistance mutation in circulating tumor DNA before scans showed progression. (FDA's first ctDNA-guided approval, Sept 4 2026) The regulatory door for ctDNA is opening. But the right read, the one which survives scrutiny, is that ctDNA there was used to select and time the treatment, and the approval itself rested on a progression-free-survival benefit from a randomized trial. The gate rewarded a proven clinical benefit, not the biomarker alone. So the door is opening, and the standard behind it is unchanged: bring me evidence that the drug helps patients, not just evidence that it moves a number.

And that powerful standard is exactly why this saga cannot end in a shortcut, no matter how strong the early signal is. Even the deepest ctDNA declines are absolutely a conviction, however, not yet an approvable proof, because ctDNA is not a validated surrogate endpoint in colorectal cancer. The anti-metastatic promise, which may be leronlimab's greatest value given that metastasis causes the overwhelming majority of solid-tumor deaths, is absolutely very difficult to prove, you cannot point to a single prevented lesion in a single patient, and the field knows it, which is why time-to-new-metastasis endpoints and randomized comparison exist for exactly this problem. (Metastasis-prevention endpoints and the difficulty of proving them, PMC) u/twinter11 reasoned his way straight to that measurement problem from first principles this week, and he was right: the deepest good this molecule may do is also the slowest to prove. That's a trial down the road. But even this gate demands hard proof. The only way around it is through it.

Yet even here, on this bleak note, a door may be opening: twinter reasoned this week that a real-time cellular readout of the seeding process itself, the kind Creatv Bio's blood-based assay is built to capture, could one day let us see suppressed metastasis earlier and prove it with fewer patients than the old slow count of new lesions ever required. (CAMLs predict recurrence and metastatic outcome, PMC) If that layer holds, the hardest thing to prove becomes provable sooner. Held loosely, as twinter would says. He gets my bravo! Realize that there is no evidence that the contract with Creatv Bio was ever cancelled. They very well maybe accumulating all of the CAML data and CTC data alongside Natera, so I wouldn't be surprised if in January, we actually do own confirmatory, despite it being retrospective, evidence of vanishing or prevented metastases.

The Provisions for the Crossing

And this is the part which divides a saga which ends somewhere inside the wilderness from one that crosses the sea to the destination on the far side: the company makes provisions for the crossing rather than starving before it.

CytoDyn closed financing that funds it well past its own reckoning, so it is not negotiating from desperation into its most important data. CytoDyn handed the molecular tracking and the comparator data to a specialized diagnostics partner rather than building that from nothing, its collaboration with Natera drawing on a database of more than two million plasma timepoints. (Natera and CytoDyn strategic collaboration, June 2026) CytoDyn is funding manufacturing readiness and regulatory infrastructure, the unglamorous provisions a company only lays in when it means to carry its own discovery through the narrows. (CytoDyn use of proceeds, financing release) And its CFO carried the standard to an international partnering forum, because the hardest truth of this industry is that the small company invents and the large company delivers, roughly 90% of big pharma's recent launches carried a significant component that came from the outside. (Big pharma launches roughly 90% sourced from outside innovators, RBC Capital Markets) That is the crucial turn this saga takes, and it is why I no longer cast Big Pharma as the enemy: in this story, the powerful houses are not the army we would face at the gates; rather, they are the allies whose ships can later carry our discovery to every sea shore on their side of the narrows, which otherwise, our small company never could reach alone. The victory is not defeating them. It is joining them from strength and that is CytoDyn's destination.

The Reckoning

So here is where the road arrives. The wandering of the wide wilderness is nearly over, not because the destination is guaranteed, but because the test which decides it, is finally at hand. In October, at the European congress,

• the first light,
• an interim look,
• a poster,
• a tease of what the fuller data may hold.

And in January, at the gastrointestinal cancer meeting,

• the reckoning itself,
• the confirmed response rate,
• the durability,
• the first real answer to whether the molecule which survived the wilderness can actually defeat the stromal fortress which has broken everything else that came before it.

I hold the line which makes these others above worth trusting, because this saga, without it, would be a fairy tale.

• The mechanism is real and continues being validated.
• The provisions are laid in.
• The captain is steady.
• The gate's standard is clear.

But the molecule still has to prove, in confirmed human data, that it does what the mechanism says, and drugs that make elegant sense fail at this gate routinely, adagrasib is this week's proof of that. So the reckoning is real, and the outcome is not written yet. This is what makes it a Reckoning and not a coronation.

Understand the shape of what we witness, because it alters how the quiet is sensed. This is not a company drifting toward an ending. It is a company that has carried a discovery through a winding wilderness that should have killed it; a company that is provisioning to navigate through the last stretch of narrows, under its own power, with a steady, stable captain at its helm and a validated mechanism and once through the narrows gate, allies who it intends to join up with, rather than defeat; a company arriving, at last, at the one stretch of the road where the entire journey is now put to the test. The disease is the adversary. The data is the arbiter. And the road which has run now for years and years, today, has narrowed only to a matter of weeks.

The wandering ends where every true saga ends, not in prophecy, but in the moment the thing is finally put to the test and answers for itself. That moment is January. The long road has nearly run its length. What waits at the end of it is not written yet, and that is exactly why we have come all this way to witness and partake.

Recognition where it is due, because a saga as long as this, is never carried by only one voice: to u/twinter11, whose questions this week reached from

• the adagrasib lesson to
• the problem of actually measuring the vanishing metastases, to
• the reason why a checkpoint inhibitor alone does not and can not force the flag, to
• the reason why, of all these weapons, leronlimab is the one that is not a killer;

to u/sunraydoc2, u/Ibelieveincydy, u/BuildGoodThings, and to every reader who brought a paper, a catch, or a correction and there are too many to list without making this heavier than it could be.

Since today is Labor Day, I took Sunday off and produced this summary. Thank you for helping me with the thinking. This is a board who thinks together. We walk this road together. And together is how we'll read the pages that January writes.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is a synthesis and interpretation of public information and published literature, cast in narrative form, not a prediction of clinical, regulatory, or commercial outcomes, and not a claim that any result, approval, or partnership will occur. The leronlimab-plus-Trodelvy pairing described is my own mechanistic hypothesis, not a trial or company-stated plan; the leronlimab-plus-checkpoint-inhibitor pairing is an in-trial hypothesis that is also unproven. Aging and microenvironment findings cited derive from mouse and laboratory studies and validate the CCR5 target, not leronlimab specifically. The adagrasib and other-company approvals discussed concern different products. Leronlimab's efficacy is unconfirmed, with interim data anticipated at ESMO in October 2026 and confirmed data at ASCO GI in January 2027; referenced figures are early, reflect combination therapy and lower-dose cohorts, and are not evidence of survival benefit. ctDNA is not a validated surrogate endpoint for approval in colorectal cancer. The company has disclosed substantial financing needs and going-concern considerations in its filings, and preparation activities do not indicate any filing or transaction is assured. Read the primary sources and reach your own conclusions rather than adopting mine.

There is a kind of technology which changes the world twice. The first time, it barely gets noticed. The second time, it is expounded everywhere, permitting everyone to forget that there ever was a different way. Chemotherapy is that technology, so let's walk through both trajectories, because the second one happens right now, as we speak, and leronlimab stand's right at the exact center and heart of it.

The First Trajectory: The Inability To Aim

Chemotherapy is one of the most important inventions in the history of medicine. It has saved millions of lives. And for its entire first life, it worked the only way it knew how, by flooding the entire body with poison and hoping the tumor died faster than the patient became harmed. It does not aim. Cytotoxic chemotherapy acts on healthy and malignant cells alike, and its indiscriminate action on healthy tissue is exactly what causes the debilitating side effects patients endure. Chemotherapy is the machine which sprays its force everywhere at once and we accept the collateral damage because, for decades, there was no other alternative and there never had been.

That was the first life. A blunt instrument, powerful and crude, that saves lives by enduring the damage to the whole in order to reach a part.

The Second Trajectory: Chemotherapy That Learned To Aim

Now see chemotherapy get taught to aim, because this is not hypothetical, it is already an approved treatment.

Gilead's Trodelvy (sacituzumab govitecan) is, at its heart, a chemotherapy drug which has been strapped onto a guided missile. It is an antibody-drug conjugate: a monoclonal antibody like leronlimab which recognizes a specific marker called Trop-2 on the surface of tumor cells, chemically linked to SN-38, a topoisomerase-I inhibitor, which is the active, cell-killing metabolite of the classic chemotherapy irinotecan. In Gilead's own words, Trodelvy is intentionally designed with a hydrolyzable linker attached to SN-38, a topoisomerase-I inhibitor payload, delivering potent activity to Trop-2-expressing cells.

Read that carefully, because it is the point. Trodelvy is chemotherapy, the same category of DNA-damaging poison, but instead of spraying it throughout the whole body, the antibody carries it and aims it directly at the cancer cell which displays Trop-2. The antibody finds only the tumor. The chemotherapy does the killing. The blunt instrument has been given eyes. And it works: in the ASCENT trial, Trodelvy significantly prolonged both progression-free survival and overall survival compared with standard chemotherapy in metastatic triple-negative breast cancer, which is exactly the hard, cold disease that we care about.

So that is chemotherapy's second trajectory, unfolding in real time: the poison learned to aim, and it earned an FDA approval doing so. Which raises the question this post is really about. If Trodelvy aims chemotherapy at the tumor cell, what is leronlimab aiming at, and do the two of them belong in the same sentence?

Two Different Types Of Aiming

Here is the elegant part, and it is why leronlimab is not a competitor to this drug because it is a different instrument aimed at a different target.

Trodelvy aims specifically at the tumor cell. It uses Trop-2 as an address and delivers its chemotherapy payload precisely to that address. It is a precision instrument aimed at the cancer cell itself.

Leronlimab aims at the tumor's surroundings. The tumor's microenvironment. It does not poison anything. Its target is the corrupted molecular conversation a cold tumor has with the environment around it, the CCR5 signaling the tumor uses to turn nearby immune cells and fibroblasts into tumor protectors, hypnotized to build a wall in order to shield it. Those corrupted surroundings, the cancer-associated fibroblasts and the chemokines which they secrete, become active tumor cells which shield the tumor as protection from conventional chemotherapy and help to drive tumor's chemotherapy resistance. Leronlimab aims specifically at that shield in the TME. It is a precision instrument, pointed not at the cancer cell at all, but at the fortress the cancer cell hides within.

One drug aims at the cell. One aims at the wall around the cell. And the moment you see it that way, a question becomes obvious: what happens if you aim at both?

The Trap Which Catches Inventors, And How CytoDyn Steps Around It

But, before the pairing question, there is a harder one, and it is not actually about biology at all. It is about what happens to the company that develops a breakthrough.

There is a pattern in industry which should genuinely concern anyone who owns a piece of a real innovation. A small company who proves something important, demonstrates that it works, shows the world something which once you see it, cannot be unseen, and then discovers that proving a drug and delivering a drug are two entirely different mountains to ascend. The first mountain, CytoDyn traverses. The second mountain, with the likes of late-stage trials, manufacturing at commercial scale, regulatory submission, global commercialization, is brutally expensive and requires an infrastructure a small company simply does not have. So, in the analogy, the inventor stalls at the summit of the first mountain, unable to climb the second alone, and either runs out of road or watches a larger company carry its breakthrough the rest of the way. The idea survives. The inventor does not always share in the reward.

This is not pessimism, rather, it is how the economics actually work, and the numbers are striking. One healthcare investment banker put it bluntly: of the molecules big pharma companies launched over the past five years, roughly 90% had a very significant component which came from outside, from smaller innovators. In other words, the small companies do a great deal of the actual inventing, and the large companies do a great deal of the delivering. The hard part for a small biotech has never been being right. It has been surviving long enough, and building long enough, to capture the value of being right.

Here is why that pattern is the exact trap CytoDyn maneuvers to step around, rather than fall into. The costs of bringing a drug through late-stage development and to market, FDA approval, rigorous trials, commercial-scale manufacturing, are extremely daunting for a small company, which is why many biotechs partner with larger players who are able to supply the resources and infrastructure in order to carry a product through late-stage development and into a patient's hands. The point of partnering is to transfer the development cost and regulatory risk that are particularly heavy in expensive late-stage work a biotech cannot fund alone, in exchange for upfront cash, milestones, and royalties, while the biotech retains upside.

Now take look at what CytoDyn is actually doing, and read it against that pattern. It is not trying to climb the second mountain entirely alone, and it is not passively waiting to be rescued either. It is deliberately delegating the necessary pieces a small company should delegate while holding onto the value it should keep.

• It handed the trial-sample analysis and the comparator data to a specialized diagnostics partner rather than building that capability from scratch; its collaboration with Natera has Natera assessing the CLOVER samples and supplying real-world comparator data from a database of more than two million plasma timepoints.
• It pursues pharmaceutical partnerships to shoulder the commercialization and late-stage burden which no company its size is able to carry alone; management has stated plainly that it continues to evaluate strategic partnership opportunities as its data matures.
• It presents at international partnering forums where exactly those counterparties gather, its CFO, Robert Hoffman appeared at the Asia Bio Partnering Forum in Singapore.
• And it funds its own manufacturing readiness and regulatory groundwork such that when it comes to the table, it comes as a prepared partner rather than as a desperate one, its most recent financing names manufacturing readiness and regulatory and compliance infrastructure among the intended uses of proceeds.

CytoDyn is a company distributing the second-mountain workload to those who are built to carry it, while positioning to keep a meaningful share of what its own invention is worth.

That is the stark difference between an inventor who gets orphaned by their own breakthrough and an inventor who builds a structure able to carry it forward. The orphaned one tries to do everything alone but stalls, or waits passively only to get picked over. The inventor who captures their value delegates the heavy load of infrastructure to partners who are built exactly for that load, which is precisely the strategy CytoDyn executes, while retaining ownership and upside in what they discover. Delegation is not weakness here. It is the specific required move which keeps a small company from becoming a footnote to its own invention.

The Established Pairing: Leronlimab And A Checkpoint Inhibitor

Before the new idea, I restate the one we already know, as it is the template.

The thesis we have discussed for months is Prime and Pair with an immune checkpoint inhibitor, (ICI). Leronlimab primes: it dismantles the stromal wall and, in doing so, drives the tumor to raise a specific surrender-flag called PD-L1. Then the ICI pairs: a Keytruda-class antibody is brought in to strike down precisely that PD-L1 flag, allowing the freed and now undeceived immune system to finish the tumor. This is a precise mechanistic handoff, the primer creates the exact target the pairing agent requires. It is the reason a checkpoint inhibitor, which does nothing in a cold tumor on its own, could work after leronlimab has done its priming. That pairing is not proven just yet, it is what the CLOVER rollover and the coming data are built to test, but it is a defined, in-trial hypothesis with a clear logic.

Hold that template, because the new idea rhymes with it, but works differently, and the difference is worth being honest about.

A New Hypothesis: Could Trodelvy Be A Pairing Agent Too?

Now, a genuinely interesting, and genuinely speculative question. Could leronlimab pair with Trodelvy in a way comparable to how it pairs with a checkpoint inhibitor? I want to be clear that this is a hypothesis, mine, built from mechanism, not something in a trial or in a label. But it is a coherent one, and it is worth laying out because it points towards a real experiment.

The logic runs like this. Trodelvy is an antibody-drug conjugate, and the eternal problem with any drug that has to reach a tumor is in actually getting there. A cold tumor's fibrotic wall physically obstructs drug delivery; that wall blocks blood vessels, and shields the tumor from the toxic therapy; is is the same wall that resists conventional chemotherapy. So here is the hypothesis: if leronlimab dismantles that wall, it could open the door for Trodelvy's aimed chemotherapy to actually reach the tumor cells which it targets. Leronlimab thins that fortress permitting Trodelvy's guided payload to get in. And there is a second layer: Trodelvy's SN-38 payload kills tumor cells in such a way which can release tumor antigens and provoke immune attention, and leronlimab's now repolarized, un-deceived and un-suppressed tumor microenvironment immunity could be better positioned to capitalize on that repolarization, thereby turning cell death into a broader overall immune response.

Notice how this differs from the ICI pairing, because honesty requires the distinction. With the ICI, leronlimab creates the (PD-L1) target that the pairing ICI agent strikes, a flag-and-strike handoff. With Trodelvy, leronlimab would not be creating Trodelvy's target, Trodelvy aims via Trop-2 on its own, it would be clearing the terrain such that Trodelvy's aim can land, and then it would amplify the aftermath. It is a complementary-mechanisms pairing rather than a flag-and-strike pairing. Both are pairings. They are just different kinds, and I am not blurring them, because the ICI version has a defined molecular handoff and the Trodelvy version is a terrain-and-amplification hypothesis.

And the timing question, pre, post, or simultaneous, is exactly the kind of thing such a hypothesis raises and cannot yet answer. Prime first with leronlimab to thin the wall, then bring Trodelvy in to a tumor it can now reach? Run them together so the wall comes down as the payload arrives? Use Trodelvy first to debulk, then leronlimab plus an ICI to mop up what the immune system can now see? Each sequence is a different bet, and which one, if any, works is precisely what a trial would have to determine. The honest statement is that leronlimab plus a Trop-2 ADC is a coherent, testable idea across all three sequences, not a proven regimen in any of them.

Why This Matters Even More This Week: The Door The FDA Just Opened

And here is where the news gives the whole picture a sharper edge, and where I want to credit ibelieveincydy, who flagged it and got out of bed early on a Saturday to do so.

This week the FDA granted accelerated approval to a breast cancer therapy, and did something it had never done before: it approved a treatment guided by detecting a resistance mutation in circulating tumor DNA, in the blood, before imaging scans show the disease progressing. That is a real and encouraging signal about the regulatory climate, the FDA is increasingly becoming more comfortable building ctDNA into approvals and granting accelerated approvals based on surrogate and intermediate endpoints in serious diseases with unmet need.

I want to hold the line ibelieveincydy and I have both been careful about, because it makes the point durable. In that approval, ctDNA was used to select and time the treatment, to identify exactly which patients to switch and when, and the approval itself rested on a progression-free-survival benefit from a randomized trial, with confirmatory survival data still required. So it establishes ctDNA as an accepted tool for patient selection, not yet as a validated surrogate that proves a drug works on its own. That distinction matters for us: it shows the regulatory door for ctDNA opening wider, which is a genuine tailwind, while the path through it still runs through real clinical confirmation. Encouraging climate, unchanged bar. Both true, and ibelieveincydy was right to wake up for it.

The Honest Edge

I hold the line I always hold. Everything above is mechanism and hypothesis, not confirmed outcome. Trodelvy is real, approved, and genuinely effective, that part is established. Leronlimab's precision at the microenvironment is real and documented. But the leronlimab-plus-ICI pairing is unproven and in testing, and the leronlimab-plus-Trodelvy pairing is a hypothesis I am proposing from mechanism, not a regimen anyone has run. Complementary mechanisms which make elegant sense on paper still have to survive a trial, and combinations fail routinely. The size of leronlimab's own clinical payoff is unconfirmed until the data lands, first at ESMO in October, then in a mature way at ASCO GI in January. No hypothesis about pairing partners matters until leronlimab first proves its own contribution.

But understand the shape of what you are looking at. Chemotherapy's first trajectory was the blunt instrument. Its second trajectory is aiming that payload; Trodelvy is chemotherapy aimed at the tumor cell, and leronlimab is a different instrument that aims at the stromal wall around the cell. The most interesting therapies of the next decade may not be one aim or the other, but the combination of aims, the wall cleared, the cell targeted, the immune system freed, layered in the right sequence. Leronlimab pairs with a checkpoint inhibitor by a defined molecular handoff we are testing now. It could, hypothetically, pair with a Trop-2 ADC like Trodelvy by clearing the terrain its aim needs and amplifying the aftermath. And the regulatory door for exactly this kind of biomarker-guided, unmet-need oncology is opening wider, as this week showed.

Two kinds of aiming. One established pairing in trial, one hypothetical pairing worth testing. And a company standing right at the point where chemotherapy's second life, immunotherapy's cold-tumor frontier, and the microenvironment all meet.

But the science is only half of what matters here, because history is full of inventors who aimed true but still got orphaned by their own breakthrough. The thing to watch for is not only whether leronlimab can aim at everything the tumor uses to survive, but whether the company is building the structure, the partners, the manufacturing, the regulatory groundwork, to carry that aim across the second mountain rather than stall at the summit of the first. On the evidence presented, it is doing exactly that: delegating what it should delegate, funding what it should fund, and positioning to keep a share of what it discovers. The blunt instrument now aims. The inventor positions not to get left behind. Both of those get their first real test in the months ahead.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis and interpretation of public information and published literature, not a prediction of clinical, regulatory, or commercial outcomes. The leronlimab-plus-Trodelvy combination described is my own mechanistic hypothesis, not a trial, regimen, label, or company-stated plan, and no such combination has been demonstrated; the leronlimab-plus-checkpoint-inhibitor pairing is an in-trial hypothesis that is also unproven. Trodelvy (sacituzumab govitecan) facts are drawn from its approvals and the cited literature and describe that drug, not leronlimab. Leronlimab's efficacy is unconfirmed, with interim data anticipated at ESMO in October 2026 and confirmed data at ASCO GI in January 2027; referenced early figures reflect combination therapy and lower-dose cohorts, are not evidence of survival benefit, and drugs that make elegant mechanistic sense fail in trials routinely. The FDA accelerated approval discussed concerns another company's product and rested on a progression-free-survival endpoint with ctDNA used for patient selection, not on ctDNA as a validated efficacy surrogate; it does not establish any pathway for leronlimab. The company has disclosed substantial financing needs and going-concern considerations in its filings. Read the primary sources and reach your own conclusions rather than adopting mine.

It has been a loud week on the board, a new aging paper, a bone-marrow mechanism, a caution flag about the drug's own target, biomarkers, timelines, and a lot of dense biology flying past. If you are newer here, or even if you are not, some of it may have felt like a pile of disconnected findings. So this Sunday I want to do something simpler than usual: not break new ground, but tidy the ground we already have. Let's lay the pieces side by side, show how they fit, and then say plainly and modestly what the next two dates could reasonably show. No prophecy. Just the shape of it.

One idea holds most of the week together

Almost everything that landed this week is a variation on a single theme, and once you see the theme, the pile stops looking like a pile.

The theme is this: there is one signaling conversation in the body, a chemical call named CCL5 and a receiver named CCR5, and that conversation turns out to be involved in a startling number of things. It is an ancient, general-purpose piece of biological machinery, and the body uses it in many rooms. That is the whole reason a single drug aimed at that receiver keeps showing up in conversations about diseases that otherwise have nothing to do with each other.

This week alone, we saw that conversation appear in three different rooms.

• In cancer, tumors broadcast CCL5 to recruit and corrupt the immune cells around them, building a wall, and blocking the receiver can help strip that wall away.
• In aging, a new high-quality paper showed that worn-out immune cells broadcast the same CCL5 signal into the bone marrow, tilting the body's blood factory toward inflammation, and blocking the receiver in old mice rebalanced it.
• And in the older literature we revisited, the same axis keeps turning up in memory, in muscle aging, in stroke recovery.

Different diseases, one conversation. That is not a coincidence to be amazed by. It is a clue about what the machinery is.

So if the week felt scattered, here is the through-line: you were not watching a dozen unrelated findings. You were watching one ancient signaling system get spotted in one room after another. That is the uncomplicated version.

Honesty that makes the idea trustworthy

Now, the single most important thing we learned this week is the thing which keeps the idea from running away with us, and I want to put it front and center, because it is what separates an honest thesis from hype.

The same receiver is not always the villain. This week a peer-reviewed paper showed a setting, protecting the brain after radiation injury, where CCR5 signaling was the helpful mechanism, the thing doing the protecting. Blocking it there would be the wrong move. So the accurate version of the breadth idea is not "this receiver is bad everywhere, block it everywhere and everything improves." The accurate version is "this receiver is a central hub in many conditions, and in many of them its activity drives disease so blocking it appears to help, but the direction depends on the room." That is a more careful claim, and a more credible one, and holding it is exactly what should make you trust the rest.

Why does this matter for how you read the news? Because it tells you the enthusiasm has a boundary, and a thesis which names its own boundary is stronger than one that pretends it has none. The breadth is real. It is also not infinite. Both are true, and holding both is the whole discipline.

The part people find most confusing, uncomplicated

The single most common source of confusion on this board is the drug's own trial design, so let's settle it in plain terms, because it is actually simpler than it looks once you see the logic.

The mechanism has a two-step name, Prime and Pair, and it makes two separate promises. First promise: the drug Primes,

• it changes the tumor's environment
• and, notably, drives the tumor to raise a specific flag called PD-L1.

Second promise: once that flag is raised, you Pair the drug with a second, already-approved kind of drug, a checkpoint inhibitor,

• that strikes down exactly that flag,
• letting the immune system finish the job.

Here is the part that confuses people: the main colorectal trial does not include the checkpoint inhibitor up front. People ask, reasonably, why not just give both at once? The answer, which the company has now confirmed from the inside, is deliberate and worth understanding. They are measuring what the drug does on its own first, deliberately isolating its contribution, before adding the second drug, so that when the results come in, everyone can tell what the new drug actually contributed versus what the existing chemotherapy backbone did. If you throw everything in at once and the tumor shrinks, you cannot tell which ingredient did the work. By holding the checkpoint inhibitor back and only adding it later, at progression, the trial is built to answer the one question a future partner and the regulators will both ask first: what does this drug add? So the design that looks like an omission is actually the design doing its job. It is trading a fast, muddy answer for a slower, clean one.

That single reframe dissolves most of the confusion. The trial is not missing a piece. It is sequencing the pieces on purpose, so the answer means something.

What we can honestly expect in October, stated modestly

Now the part you actually want, and I am going to keep it deliberately modest, because the honest version is more useful than the grand one, and because I would rather be right than loud.

October is an interim look, a poster at a European cancer conference, not the final verdict. It shows a snapshot of a trial which is still running, weighted toward the patients who enrolled earliest and have the most scans behind them. So here is a reasonable, non-inflated expectation.

The bar to clear is low and well-documented. The current standard of care in this setting, the same chemotherapy backbone without the new drug, produces a confirmed response, meaningful tumor shrinkage, in only about 6% of patients in its registration trial, and closer to only 3% in the real world. Roughly half of patients on that backbone see any shrinkage at all, and far fewer see enough to count as a formal response. That is the graveyard this drug is being tested against.

So a modest, credible positive at October would look like this: a response rate that is clearly, if not dramatically, above that 6% floor, call it landing somewhere in the low double digits, 18-30%, together with the deep reductions in tumor DNA the company has already signaled, and evidence that those responses are holding rather than fleeting. I am not going to promise a specific number, and I would distrust anyone who does at the interim. But "meaningfully beats the roughly 6% benchmark, say 3-5 times, with durable-looking early responses and the biomarker story intact" is a reasonable thing to hope for and a modest thing I think, to watch for. That would not be a knockout. It would be a solid, encouraging interim that keeps the door genuinely open, and in a disease where almost nothing works, clearing that low bar convincingly by 3-5x, is certainly worth something.

What would make October interesting beyond that is the dose question, whether the higher dose outperforms the lower, by how much?, and any early hint of the PD-L1 priming actually happening in patients. Those are the threads to pull on. But hold October as "the encouraging interim," not "the answer."

What January can honestly show

January, at a gastrointestinal cancer meeting, is the more mature readout, more patients, more scans, the confirmed response rate that actually adjudicates the question. This is where the interim either firms up or does not.

A modest, credible January outcome, the kind that falls above my usual high bar for this company but stops well short of fantasy, would be a confirmed response rate that holds in that clearly-above-benchmark range, 5-7 times, (30-50%), ideally with a visible separation between the two doses of 350mg and 700mg, paired with progression-free survival trending better than the backbone alone, (possibly nobody has died yet and hospital stays have minimized) and the tumor-ctDNA and PD-L1 story reinforcing rather than contradicting the radio-imaged scans. If that is what January shows, it would be a real, defensible signal that the priming works and that the drug adds something on top of the standard of care, enough to bring a serious partner to the table and enough to open a genuine conversation with regulators about an expedited path.

Notice what I am not saying.

• I am not saying approval.
• I am not saying a specific price or a specific deal.
• I am not saying survival is proven, that takes far longer to mature than either of these dates allows.
• And I am not saying the checkpoint-inhibitor pairing is validated yet, that is what the rollover arm tests over the following months.

What I am saying is narrower and, I think, honest:

• October can reasonably show an encouraging interim above a low benchmark,
• and January can reasonably show a confirmed version of that,
• and if both land, the drug will have done the one thing it most needed to do, demonstrate its own contribution in a disease where the current tools barely work.

The shape of it

So here is the whole week, uncomplicated, in a few lines.

• There is one ancient signaling conversation, CCL5 and its receiver CCR5, that keeps appearing across cancer, aging, and more, which is why one drug aimed at that receiver has such surprising reach.
• That reach is real but not unlimited, this week's most important lesson was that the same receiver is protective in some settings, which is the boundary that keeps the thesis honest.
• The trial that confuses people is not missing a piece, it is deliberately sequencing the pieces such that the drug's own contribution can be seen.
• And the two dates ahead can each honestly show something meaningful but bounded, October an encouraging interim above a low bar, January a confirmed version of it, neither one an approval, both of them the kind of result that would justify the years of waiting without pretending the waiting is over.

That is the shape of it.

• The mechanism is real and wide.
• The honesty is built into the trial. Its design makes sense once you see the logic.
• And the next two dates can deliver a solid, credible result without needing a miracle to be worth the wait.

Hold the excitement at full strength and the outcome with open hands, as always. We find out soon, and for once, soon is measured in weeks.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is a synthesis of publicly available research and company disclosures, not a prediction of clinical or commercial outcomes. The expectations described for October and January are my own reasoned hopes, explicitly not forecasts or guarantees; interim and confirmed trial results can fall anywhere, including well below these hopes, and drugs that make elegant mechanistic sense fail in trials routinely. The aging and context-dependence findings discussed derive from mouse and cell studies using research-tool compounds, not leronlimab, and validate the CCR5 target rather than the drug. The CLOVER figures referenced are early, unconfirmed, reflect combination therapy with a chemotherapy backbone and 350mg dosing with higher-dose data still maturing, and are not evidence of a survival benefit. The SUNLIGHT benchmark figures are drawn from published data on the standard-of-care regimen. Confirmed adjudication is anticipated at ASCO GI in January 2027. Mechanism and target validation are not clinical efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

How an Aging Body Talks Its Own Factory Into Making the Wrong Thing, and Why One Receiver Keeps Showing Up

Credit to where it is due before I begin. u/twinter11 brought a brand-new paper to the board earlier this week and, to his credit, read it himself rather than running it through an AI, which is exactly the discipline that catches what matters. And u/sunraydoc2, a day or two prior, made the larger argument which this new paper now reinforces, that the same molecular signaling we've talked about ad nauseum within cancer, may very reside as the very hub of aging itself. This post is my attempt to take these contributions, and together, distill these new findings into plain language, and connect it to all which we have been piecing together about leronlimab. If you have never heard of this drug or this company, you should still be able to follow these steps. That is the point.

Let's start with a factory, because your body runs one

Deep inside your bones resides the bone marrow. It is a factory of sorts. This is where stems cells are made. It runs every hour of every day of your life, and it makes your blood. This factory, the bone marrow, takes raw material, blood stem cells, and turns them into two broad categories of product.

• The first category is the emergency responders, called neutrophils and other myeloid cells, the immune system's blunt instruments, the ones which rush to a wound or to an infection, that cause inflammation, and clean up by force and annihilation.
• The second category is comprised of the specialists, called lymphocytes, the precise, targeted, intelligent arm of the immune system, the cells which recognize very specific threats and are able to remember them by "appearance".

A young, healthy factory maintains these two product lines in a close knit balance. Enough blunt responders to handle emergencies, enough specialists to fight with precision and memory. The balance between the two is the health we're discussing. The way we measure that balance, in a simple blood test, is a ratio called the neutrophil-to-lymphocyte ratio. Look at it as Blunt instruments over specialists. When that number is low, the factory is balanced and youthful. When it climbs, the factory is tilted toward churning out blunt responders at the expense of specialists.

Here is a fact worth pausing on, because it is the reason this whole story matters. That ratio, how far the factory has tilted toward blunt force, is one of the strongest predictors of death from almost any age-related disease we have. It rises with age in nearly everyone. A tilted factory is, in a real sense, a measure of how old your body is on the inside.

So the question which matters for human health is simple to state and has been hard to answer: what tilts the factory? What talks it into making too many blunt instruments and too few specialists as we age? For a long time the mechanism was murky. This week, a paper in Nature Aging gave a startlingly clear answer, and the answer turns out to be a conversation.

Corrupted Order

Picture the factory again. The workers are on the floor, who are the blood stem cells, do not decide on their own what to churn out. They listen for orders, which are chemical signals, that drift in from the surrounding tissues and instruct them on exactly what the body requires. In a young body, the orders are balanced, and the factory stays balanced.

Now here is what the new paper shows happens with age. A particular kind of aged immune cell, a worn-out, battle-hardened T cell, begins to accumulate inside the bone marrow itself, right inside on the factory floor. And these aged T cells do something specific: they stand in the middle of the factory and broadcast a single, insistent chemical order, over and over. That chemical order is called CCL5, aka RANTES.

CCL5 is, in effect, a corrupted instruction. It tells the factory floor: to make more blunt responders. And the factory, hearing this repeated order shouted continuously by the aged T cells who have moved in and taken residence, obeys. The factory tilts. It overproduces neutrophils, underproduces lymphocytes, and the neutrophil-to-lymphocyte ratio climbs. The factory has not broken. It has been talked into making the wrong thing by a chemical signal it cannot help but obey.

But an order only works if something has an ear to listen for it. And this is where the entire story connects to everything we care about.

CCR5 Is the Receiver

A chemical order like CCL5 sent out by RANTES does nothing on its own. It has to be received, otherwise, it's like talking into a phone which hasn't been picked up on the other end. The factory workers, the stem cells and their descendants, have to carry a receiver on their surface tuned specifically to that exact RANTES signal frequency. The paper showed that as the body ages, the factory workers upregulate that specific receiver frequency to match the RANTES signal frequency; ie: they grow more antennae tuned to the increased corrupted chemical order, so much so that they hear it louder and obey it more.

That receiver has a name you may recognize if you have spent any time on this board. It is called CCR5.

Read that again, because it is the entire reason I am writing this post. The corrupted order which tilts the aging blood factory toward inflammation, disease and sickness is CCL5. The receiver that hears it is CCR5. CCL5/RANTES speaks, CCR5 listens, and the factory tilts its output. It is the exact same signal-and-receiver pair, the exact same molecular conversation, which sits at the center of the cancer story we have been telling for years.

And so the researchers did the obvious experiment. If the problem is a corrupted order being received, what happens if you block the receiver such that the order cannot be heard?

What happens when you unplug the receiver

They took aged mice and gave them a drug which blocks CCR5, that plugs the receiver so the CCL5 order cannot get through. The result is striking. The factory rebalances. Myeloid overproduction drops. The neutrophil-to-lymphocyte ratio, which is that predictor-of-death quantity, becomes normalized toward youthful levels. Inflammatory cells stop flooding into the liver and into the lungs. Multiple markers of aging improve, and so does the animals' actual function, their muscle strength, their coordination, their metabolism. Blocking the receiver does not just quiet a signal on a chart. It makes old animals work and behave more like young ones. Their immune systems improve and function appropriately. The authors called CCR5 inhibition a potential strategy to protect against aging itself.

Unplug the receiver, and the factory stops obeying the corrupted order. That is the finding.

Why this reaches back into everything we know

Now let me connect the wires, because this is where the breadth we keep talking about stops sounding like enthusiasm and starts looking like a pattern.

For as long as we've been here on LIVIMMUNE, on this board, the story has been about a molecule, leronlimab, which blocks CCR5, that biochemical radio receiver. In cancer, we have described how tumors broadcast CCL5 that hijack the immune cells around them, to build a wall in order to suppress the attack of T cells, and how blocking CCR5 can strip and even dissolve that wall away. The receiver in the cancer discussion and the receiver in this aging discussion are the exact same receiver. The corrupted order in both is the same corrupted biochemical order. This is not leronlimab's mechanism resembling the aging mechanism. It is the same molecular conversation, taking place in two completely different rooms of the body.

And it is not only these two rooms. The same CCR5 receiver keeps turning up. Other recent work has tied CCR5 biochemical signaling to memory and to cognition, to the aging of muscle, to recovery after stroke, to neuroinflammation and to chronic pain. sunraydoc's inflammaging and u/Lab_Monkey_'s post gathered this thread and argued that CCR5 may sit at the crossroads of aging broadly, and this new paper is a direct, high-quality piece of evidence for exactly that argument. Different diseases, different tissues, one receiver, one conversation, showing up over and again.

Here is the idea that makes sense of the pattern, and it is the same one I have written about many times before. CCL5 and CCR5 are ancient, general-purpose biochemical signaling machinery, tools the body uses to coordinate immune responses across countless immunity related situations. Because the machinery is so old and so widely deployed, it also gets misused in countless situations we've been finding, corrupted by a tumor in one place, corrupted by aged T cells in another, but through the same chemical signal and the same biochemical receiver. A drug aimed at that receiver is therefore not a key cut for just one lock. Rather, it is a drug aimed at a conversation the body has wired within many rooms. That is why the same leronlimab molecule continues to earn serious scientific attention across many diseases which otherwise have nothing to do with each other. The breadth and growing pipeline is not a coincidence. It is what you would predict if the target is a shared piece of ancient machinery.

Now the discipline, because this is where enthusiasm needs to meet honesty

I have told you an exciting version, which is real. Now I owe you the honest boundaries, and they matter more here than usual, because this is exactly the kind of finding which gets oversold.

First and foremost: this paper did not use leronlimab. It used a different, older CCR5-blocking drug, called maraviroc, and genetically engineered mice. It is evidence about the CCR5 receiver as a target. It is not evidence that leronlimab specifically does any of this, because leronlimab was not in the study. The honest way to hold it is that it validates the target leronlimab happens to hit, not the drug itself.

Second, this is a mouse study. Old mice were rejuvenated on several measures, which is genuinely encouraging, but the history of aging research is full of things that worked beautifully in mice and did not translate to people. Mouse aging is not human aging, and "improved function in aged mice" is a beginning, but not a promise.

Third, aging is not a disease you can actually get a drug approved for. There is no regulatory box called "aging." So even in the best case, translating this would mean targeting a specific, measurable condition, a defined inflammatory disease, a specific age-related decline, not "aging" in the abstract. The road from this paper to a human therapy is long, and most such roads do not arrive to their intended destination.

There is one honest point that pushes the other way, and I will give it its due because it is real. The paper notes that humans who are born with a naturally broken CCR5 gene, the well-known Delta-32 mutation/variant, have better outcomes after stroke and in multiple sclerosis. That is not mouse data. That is a human genetic signal suggesting that losing CCR5 function is broadly protective. So while this specific study is mice and maraviroc, it sits on top of a real human foundation. That does not prove leronlimab does anything for aging. However, it does mean the underlying idea, that quieting this receiver is beneficial across conditions, and has human evidence beneath it.

Where this leaves us

So here is the whole picture, assembled honestly. A new, high-quality paper has identified the conversation which tilts the aging blood factory of bone marrow toward inflammation and death, and it is the CCL5/RANTES commanded order heard through the CCR5 receiver frequency. Blocking that receiver rebalances the stem cell factory and rejuvenated old animals. The receiver is the same one leronlimab is built to block, and it keeps appearing at the center of disease after disease, which is exactly what u/sunraydoc2 argued and exactly what the breadth of this whole LIVIMMUNE program has hinted at. That convergence is real and it is striking, and u/twinter11 was right to bring it here.

And leronlimab, specifically, still has to prove itself where it is actually being tested, in cancer, in a trial reading out this coming January, in humans, on hard endpoints. The aging story is a magnificent view of where the biology could someday lead. It is not the thing being decided next. What is being decided next is whether this drug, in the disease it is actually in, delivers the confirmed results that turn an elegant and far-reaching mechanism into a proven therapy. The receiver is real. Its reach appears vast, including every person on Earth. And the proof, as always, is the data that has not actually landed yet.

The corrupted biochemical order is real, and the body has wired that same receiver into more rooms than anyone has expected. Whether we have the right drug to quiet it, in the room that counts first, is what January begins to answer.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is an explanatory piece about published mechanism, not a prediction of clinical or commercial outcomes. The Nature Aging study discussed used maraviroc and genetically modified mice, not leronlimab, and demonstrated effects in aged mice, not humans; it is evidence about the CCR5 target, not about leronlimab's efficacy in aging, which has not been tested. Aging is not an approved therapeutic indication. Leronlimab's efficacy in its actual clinical settings is unconfirmed, with confirmed oncology data anticipated at ASCO GI in January 2027; the CLOVER figures referenced elsewhere are early, reflect combination therapy and 350mg dosing, and are not evidence of survival benefit. Mechanism and target validation are not the same as clinical efficacy, and CCR5-directed approaches have a mixed clinical translation record. Read the primary sources and reach your own conclusions rather than adopting mine.

I want to tell the strangest true story in biology, and then show that leronlimab's entire mechanism is a single chapter of it. If you are new to this board, it is not necessary to know anything about the science to follow this. If you have been here for years, I think you will still see the drug in a way which you have not seen it before. Stay with me, because by the end of it, the reason a CCR5 antibody might matter across so many different cancers and platforms won't be a list of facts which need to be memorized. It will be an idea you cannot forget.

The Deal Every One of Your Cells Made

Start with a fact which sounds made up but is not. Every single one of the roughly thirty to sixty trillion cells in your body carries a complete, working copy of everything it would require to live entirely on its own. To eat on its own. To divide on its own, without permission, without limit. That is not a flaw hiding in your cells. That is the default setting, the original way of life, inherited from the single-celled organisms which every animal is built upon.

Cooperation, a body, you, is the exception. It is the thing built upon that ancient default, and it was built more than two dozen separate times across unrelated branches of life. Roughly a billion years ago, in the lineage which has become you, where a group of cells struck a deal: stop competing, stay comingled & attached, divide the labor, and police the ones who break the rules. Your body is that deal, upheld silently, cell by cell, trillions of times daily, across the span of your entire life. Most of the time it holds. You never notice it was ever a deal at all.

And then, sometimes, in one cell out of tens of trillions, it does not hold.

Cancer Is Not An Invader. It Is A Memory.

Here is the part that reframes everything. When a cell becomes cancerous, it is not being invaded by something foreign. It is not learning a new trick. It is remembering an old one. It is falling back to the ancient, every-cell-for-itself program which predates the entire cooperative arrangement, and that has been sitting silenced in its genome throughout the entire time span.

This is not a poetic flourish. It is a serious and growing scientific theory called the atavism theory of cancer, and the peer-reviewed literature states it almost exactly the way I just did: cancer represents the re-deployment of ancient, unicellular programs that support survival of the cell at the expense of the host and break the contract of cooperation required for multicellular life. Researchers have confirmed, using techniques that date genes by their evolutionary age, that cancer cells systematically over-express the evolutionarily oldest genes, the unicellular ones, and rewire themselves back toward that ancient logic. A cancer cell, in the most literal molecular sense, is a cell which has remembered how it used to live back before there was a consolidation of you to even be a part of.

Hold that picture, because now the drug walks onto the stage, and it fights on exactly this battlefield.

The Wall The Ancient Cell Builds, And Who It Recruits

A cell that has reverted does not just start dividing. It rebuilds the conditions of the ancient, hostile, single-celled life around itself. It walls itself off. It recruits help. And this is where a specific molecular conversation matters, because it is the one which leronlimab interrupts.

The reverted tumor cell sends out a chemical signal, a chemokine called CCL5, aka RANTES, into the tissue around it. Think of it as a distress beacon broadcast into the surrounding environment. And there is a class of your own immune cells, macrophages, which carry the receiver for that signal on their surface, a receptor called CCR5. When CCL5 reaches CCR5, the tumor effectively hijacks those macrophages, turning cells which should be attacking it into cells that protect the tumor, that build its wall of scar-like tissue, and that shut down the rest of the immune response. The tumor recruits your own coalition members and flips them around to the ancient side.

This is documented in human tumors, not just theorized. In the actual tissue of human colorectal cancer that had spread to the liver, blocking CCR5 flipped those hijacked macrophages back from the tumor-protecting state to the tumor-attacking state. And the reason this matters so broadly is that CCR5 is not a colorectal quirk. The CCL5-CCR5 axis is one of the general tools the ancient program uses to drive invasion, metastasis, and immune suppression across many tumor types, which is why the recent literature keeps identifying CCR5 blockade as a way to reprogram the tumor's environment and restore an anti-tumor immune response.

So here is leronlimab's first move, in the language of the story: leronlimab is a molecule which plugs the CCR5 receiver. It binds CCR5 and blocks it, such that the tumor's distress beacon can no longer summon and thereby corrupt your macrophages. The wall stops being built. The hijacked cells are freed. The ancient cell loses its recruited defenders. This is the prime.

Why Priming Alone Is Not Enough, And What Pairs With It

But the reverted cell has more than one trick up its sleeve, carried over from the old world, and this is where the strategy earns its name.

When leronlimab strips away the tumor's macrophage wall and the immune system actually begins to see it again, the tumor begins to play its last ancient card: it raises a flag that says do not kill me. That flag is a protein called PD-L1. It is the tumor's way of exploiting one of the immune system's own safety brakes, the checkpoint which normally stops your immune cells from attacking your healthy tissue. The tumor waves its PD-L1 flag high and proud such that the immune cell, with brake engaged, stands down. The ancient tumor cell survives by wearing a piece of the cooperative and collaborative body's own rulebook as a disguise.

This is the elegant part, the part that makes leronlimab different from a drug which simply tries to poison the tumor. Leronlimab's priming does not only free the macrophages to do their proper job. It also is the ingredient which drives the tumor to raise that PD-L1 flag higher. In laboratory models of triple-negative breast cancer, CCR5 inhibition with leronlimab increased PD-L1 expression, and in patients, leronlimab was associated with PD-L1 induction on circulating tumor cells. At first, that sounds backward, why would you want the tumor to raise its "do not kill me" flag higher? Because a flag raised high is a flag you can see, and a flag you can see is a target.

That is the Pair. We bring in a second drug, an immune checkpoint inhibitor, a Keytruda-class antibody, whose entire job is to block PD-L1, to tear down the "do not kill me" flag. Alone, in a Cold tumor, (one in which the PD-L1 flag is NOT raised), that ICI checkpoint inhibitor does nearly nothing at all, because there is no flag raised and no immune cells even present to unleash, which is exactly why checkpoint inhibitors fail in the majority of solid tumors. But after leronlimab has torn down the Cold tumor wall and forced the tumor to raise the flag up, the ICI checkpoint inhibitor now has something to do. It rips down the PD-L1 flag which leronlimab helped the tumor to raise, and the freed, and now-present immune cells finish the job of destroying the tumor.

Prime, then Pair. Leronlimab reopens the door and forces the tumor to reveal its last disguise. The checkpoint inhibitor removes the disguise. And the immune system, your cooperative coalition, does what it was built a billion years ago to do: to recognize the cell who broke the deal, and it enforces the rules.

Why This Reaches So Much Further Than Just One Cancer

Now you can see why the people on this board get so excited about a single antibody across so many diseases, and it is not hype, it is the logic of the story.

If cancer is, at its root, a reversion to an ancient single-celled program, and if the CCL5-CCR5 conversation is one of the general tools which an ancient program uses to wall itself off and suppress the collaborative coalition, then a drug which blocks CCR5 is not a key cut for just one specific lock. It is aimed at a shared vulnerability of the reverted state itself, wherever that reversion may occur. Colorectal, breast, brain, prostate, pancreatic and beyond, the tumors differ in a thousand different ways, but nearly all of them lean on the same ancient chemokine trick to survive, because it is one of the oldest tricks there is. The CCL5-CCR5 axis.

That is the broad spectrum. Not "leronlimab happens to work in a lot of unrelated cancers," but "leronlimab targets one of the ancient mechanisms which nearly every Cold cancer reverts back to." The breadth is not a coincidence. It is a prediction of what the drug is actually doing. And it is why the same molecule keeps showing signals in settings as different as colorectal tumors and triple-negative breast, and why researchers keep testing it in yet even more, on their sponsorship, because the thing it interrupts is older and more shared than any single cancer type.

The Honest Edge Of The Story

I will not weaken this with false certainty at the end, because the honest version is the compelling one.

Everything above is the mechanism, and the mechanism is real and documented at each step:

• cancer as atavistic reversion,
• CCR5 as a tool of that reversion,
• leronlimab freeing macrophages and inducing PD-L1 in human data,
• the checkpoint inhibitor pairing to finish.

What is not yet proven is

• the size of the clinical payoff in people,
• the confirmed response and survival numbers that turn an elegant mechanism into an approved therapy.

The early signals are very encouraging,

• deep reductions in tumor DNA,
• tumors held or shrinking,
• a clean safety record,
• but they are early, and the confirming data arrives at the January medical meeting, not before.

A mechanism this beautiful still has to survive contact with a trial, and beautiful mechanisms fail in trials routinely. So hold the story at full strength and the outcome with open hands. Both at once.

But understand what the story is, because it changes how you hear every piece of news from here on forward.

• When you read that leronlimab freed the macrophages, you will know that means it cut the tumor off from the coalition members it had corrupted.
• When you read that it raised PD-L1, you will know that is not the tumor winning, it is the tumor being forced to show the disguise the ICI checkpoint inhibitor was built to strip.
• And when you read that a CCR5 antibody keeps showing up in cancer after cancer, you will know why: it is not chasing tumors one at a time. It is standing at the exact point where a cell, in one moment out of tens of trillions, remembers how it used to live alone, and it is helping the body remember, in the same instant, the billion-year-old deal that made you one.

That is the whole thesis. A cancer cell forgets that it is part of you. Leronlimab, by blocking one ancient signal and forcing the last disguise into view, helps your own immune system remember, and enforce, the oldest agreement there is. The rest is what January is for.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is an explanatory piece about mechanism and evolutionary biology, not a prediction of clinical or commercial outcomes. The atavism theory of cancer is a serious but still-debated scientific hypothesis, not settled fact. The mechanistic claims are supported by the cited peer-reviewed literature; several steps are established in models, single studies, or retrospective cohorts and are not yet confirmed in prospective human efficacy data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER and TNBC figures referenced are early, unconfirmed, reflect combination therapy and 350mg dosing with higher-dose cohorts still maturing, and are not evidence of a survival benefit. Confirmed adjudication is ahead at ASCO GI in January 2027. Mechanism is not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

A community member, (credit to u/rogex2 for providing me the prompt), raised a question earlier this week which necessitates a full answer, because it points at something the efficacy debate typically skips over. Suppose that leronlimab does in fact succeed. Suppose that the confirmed data does arrive and hold. The next question is not only "does it work?" but, it is also "how easily is an oncologist able to use it?" And on that second question, the kind of drug leronlimab is, versus the kind of drug an individualized vaccine is, turns out to matter enormously. This is the Physician / Operational Adoption Gap, and it is a real and underappreciated edge we have.

I lay it out here on hard ground, because this is a place where the argument does not have to lean on hope. It leans on actual logistics, and the logistics are real and documented.

What "Built-to-Order" Actually Costs In The Real World

The mRNA neoantigen vaccines, the Merck and Moderna approach among them, are individualized therapies. That is their strength and also their burden. Each one has to be built and individualized, for a single patient, and that building is not trivial at all. Initially, it requires surgically obtaining tumor tissue via tumor excision, DNA sequencing that tumor, comparing it to the patient's normal DNA to find the unique tumor mutations, running those mutations through prediction algorithms to pick and choose targets of metastases, and then manufacturing a bespoke anti-tumor construct for that one single person.

The literature is blunt about what this costs in time and money. The personalized vaccine strategy faces significant challenges because it relies on individual tumor DNA profiling and custom manufacturing, which result in extended production times and high costs. How extended, and how high? A 2025 update puts the manufacturing at nine weeks, recently optimized toward under four weeks, while costs remain challenging at over $100,000 per patient. And the Operational Adoption barrier is not only price. A November 2025 review notes that logistical challenges, including the need for tumor tissue procurement and complex purification processes, have limited their broader clinical adoption despite promising immunogenicity signals.

Read that last line twice, because it is the crux of this piece. The science can be promising but the Adoption can still remain limited, because the operational friction sits between the patient and the drug. Every dose is a small manufacturing project with a weeks-long clock and a six-figure price tag.

The Cautionary Tale The Field Has Already Lived Through

This is not a hypothetical concern. Oncology has already run this kind of expensive experiment already once, and the result is instructive. Sipuleucel-T, brand name Provenge, was a personalized cancer immunotherapy manufactured individually for each patient. It launched at roughly $93,000 per course, reflecting complex production and logistics, and although it demonstrated an overall survival benefit, uptake was limited. Providers often faced significant upfront financial exposure before being reimbursed, and that friction throttled down Adoption of Provenge.

Sit with that, because it is the entire argument in one example. Provenge actually worked. It extended survival. But it still struggled commercially, because the per-patient manufacturing, the cost, and the logistics stood between the drug and the doctor/patient. Efficacy did not guarantee Adoption of Provenge. The operational model negatively did.

What "Off-the-Shelf" Means By Contrast

Now set leronlimab beside that. Leronlimab is an antibody. It is manufactured in large batches, stored, shipped, and administered just like any other off-the-shelf biologic drug. There is no tumor to excise / procure, no per-patient DNA sequencing, no bespoke construct, no weeks-long build for each and every patient, no six-figure manufacturing bill per individual treated. A Physician / Oncologist who desires to use it simply prescribes it and administers it. The drug is the same for every single patient because its mechanism of action does not depend on the patient's specific DNA mutations. It works on the tumor microenvironment, not on a custom-matched tumor antigen. As u/sunraydoc put it, it is Cold tumor agnostic.

The field itself recognizes this divide as the central practical problem in the vaccine space, which is why the literature is full of efforts to move away from full personalization. Off-the-shelf approaches can be produced in bulk at roughly one-third the cost of personalized versions and are available for immediate use. The entire trend toward "hybrid" and "shared-antigen" vaccines exists precisely because the individualized model is Operationally heavy. In other words, the vaccine field is spending an enormous effort trying to become more like an off-the-shelf drug, while leronlimab already is one.

Different Diseases, Different Moment

A reader, twinter, raised a set of questions which sharpen this comparison, because they get at something the "vaccine versus primer" framing can obscure: these two approaches are not only built differently, they are aimed at different patients at different moments in the disease. Understanding that makes the distinction cleaner, not muddier.

Start with what the Merck and Moderna vaccine is actually for. It is an adjuvant therapy, meaning it is given after surgical resection of the tumor. Its job is not to shrink visible cancer, it is to prevent recurrence. Each mRNA construct encodes up to thirty-four patient-specific neoantigens identified from the resected tumor tissue, and once administered, it primes a cytotoxic T-cell response against residual micrometastatic cells, the microscopic seeds left behind after surgery. So twinter's instinct is exactly right: the vaccine is designed for the resected patient whose margins may not be fully clear, or who may harbor micrometastatic disease, to attack those residual cells and prevent the cancer from coming back. That is its lane, and the Phase 3 melanoma result reflected the endpoints it met were recurrence-free survival and distant-metastasis-free survival, the language of prevention, not of shrinking established metastatic tumors.

This matters because it answers twinter's deeper question, whether leronlimab plus an ICI checkpoint inhibitor would mitigate the need for the vaccine, or whether the vaccine is a longer-duration one-time preventative. Really, the answer is that, as it is currently deployed, they largely occupy different settings.

The vaccine lives in the adjuvant, post-surgical, minimal-residual-disease space, preventing recurrence in patients who have already had their tumor removed. Leronlimab in CLOVER lives in the advanced, metastatic, third-line setting, treating patients with active, unresectable disease. One is trying to keep cancer from returning after surgery, the other is trying to control cancer which is currently present and progressing right now. So they are not straightforward substitutes, they are tools for different moments in the course of the disease, which is worth holding before anyone frames it as one replacing the other.

There is even a deeper current in the adjuvant literature that is relevant to twinter's line of thinking. Researchers have begun arguing that the entire challenge of adjuvant immunotherapy comes down to priming, because in the minimal-residual-disease setting the tumor-immune interaction is dim and faint and the immune system requires help in getting activated at all.

One 2025 analysis frames it plainly: adjuvant therapy targets micrometastatic minimal residual disease, a context where immune priming may be limited, and effective adjuvant immunotherapy would require agents that actually enhance priming. The vaccine is one such priming agent, boosting the immune system by teaching it what to look for.

And this is where twinter's boldest hypothesis enters, the idea that a CCR5 blocker may turn out to be the main ingredient even beyond Cold tumors, even in Hot Illuminated settings assumed not to need it. I want to be careful here, because that is twinter's speculation, not established fact, and I label it as such.

Leronlimab's demonstrated role is in Cold tumors, and whether CCR5 blockade contributes meaningfully in Hot, Illuminated tumors or in the adjuvant priming setting is not yet known; it remains an open question, not a proven claim. But it is a legitimate question to sit with, because if priming is the universal bottleneck the adjuvant literature increasingly says that it is, then a broad-based, off-the-shelf priming mechanism is at least worth asking about across such settings. I would not assert that it works there. I would say only that twinter's instinct points at a real open question the field itself has not yet closed, and it is the kind of question, that within the coming years of data, not in this post, but surely will come to answer. And twinter's related question, how much the CCR5 axis contributes in vaccine cases that fail, is equally open and yet unanswered; we simply do not have that data.

So the setting distinction actually reinforces the Operational Adoption argument rather than complicating it. The vaccine's home is in adjuvant recurrence-prevention within resected patients, a per individualized-patient-manufactured product for a defined post-surgical window. Leronlimab's home, at least for now, is active metastatic disease, an off-the-shelf agent for patients who require treatment today. Different diseases, different moments, and the operational contrast holds across both.

Why This Is An Edge

If leronlimab proves itself out, then it arrives as a drug the delivery system is already built to handle. No new cold-chain-to-the-sequencer logistics, no weeks of manufacturing lag between diagnosis and dose, no six-figure per-patient production cost, no reimbursement standoff over a bespoke product. An antigen-agnostic, batch-manufactured, off-the-shelf Primer for Cold tumors would be, Operationally, one of the easiest things in oncology to Adopt at scale, in exactly the population, microsatellite-stable colorectal and the other Cold tumors, where nothing currently works. The efficacy question and the adoption question are different questions, and leronlimab's molecular structure gives it a strong answer to the second one independent of the first.

Now the honest line, I have to give, because it is the reason the bold one is worth trusting. This entire argument is about Adoption, not Efficacy. Being easy to deliver is worth nothing if the drug does not work, and whether it works remains January's question, unconfirmed until the adjudicated data arrives. The Adoption Edge is a multiplier upon success, not a substitute for it. A drug that is trivial to administer and does not help patients helps no one. So this is not a reason to believe that leronlimab works. It is a reason to believe that if it works, it is unusually well-positioned to reach patients very fast, which is an absolutely real and separate advantage, however, held in its proper place.

There is also a fair caveat on the comparison itself. The individualized vaccines are pursuing documented benefit, the Merck and Moderna melanoma data apparently are real, and the manufacturing timelines seem to be improving toward four weeks. So this is not a claim that vaccines are bad medicine. It is a narrower and sturdier claim: an off-the-shelf mechanism is Operationally easier to Adopt than a build-to-order one, the field's own literature says so plainly, and Oncology has already seen a working personalized therapy struggle on exactly these grounds. Leronlimab, if it delivers, does not carry that burden at all.

So the Operational Adoption gap is real, it is documented, and it favors the off-the-shelf Primer. Whether leronlimab is that primer is what the confirmed data decides. But the shape of the advantage is clear now, and it is worth understanding before January, such that when people weigh what a proven primer would be worth, they weigh not only whether it works but how fast and how widely it could reach the patients who need it. Build-to-order is powerful but slow to deliver while being astronomically expensive per patient. Off-the-shelf is ready day one at least 2/3 cheaper. That difference is not everything. But it is not nothing, and in a disease where patients are out of time and probably out of money, being ready and cheaper matters.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published literature on cancer vaccine manufacturing and adoption, not a prediction of clinical or commercial outcomes. The comparison concerns operational and logistical adoption, not clinical efficacy; leronlimab's efficacy in colorectal cancer is unconfirmed, with the CLOVER figures early, reflecting 350mg dosing with the 700mg cohort still maturing, and confirmed adjudication ahead at ASCO GI in January 2027. The individualized vaccines discussed have demonstrated genuine clinical benefit in their settings; nothing here disputes their efficacy. Ease of adoption is not evidence of efficacy, and a favorable operational profile does not establish that leronlimab works. Mechanism and logistics are not clinical benefit. Read the primary sources and reach your own conclusions rather than adopting mine.

I am going to make the strongest version of this argument, because the record now supports boldness, and because the timid version has been underselling something which deserves to be said plainly. So let's say it plainly.

There is a chokepoint in oncology. A narrow passage where nearly the entire checkpoint-inhibitor industry has to pass through if it wants to keep growing, and which almost none of them can currently pass through. Whoever holds a reliable way through that passage does not hold a drug. They hold the terms of trade for a hundred billion dollars of franchise revenue. And the data now emerging suggests, without yet proving, that a small company in Vancouver, Washington may be holding exactly that.

That is the claim. Here is the case for it, built from the published record, older and brand new, with the honest limits kept in full view, because a bold argument which hides its weaknesses is just a loud one.

The Passage Almost No One Can Transit

Checkpoint inhibitors are the most commercially successful class of cancer drugs ever created, and they fail in the vast majority of solid tumors. Both things are true, and the second is the industry's quiet catastrophe.

This is not a fringe position. It is the settled consensus of the field, stated flatly across the literature. In the definitive 2024 review of the subject, tumors are sorted into "Hot" and "Cold," where the cold ones lack the infiltrating T-cells a checkpoint inhibitor requires to kill, and often harbor immune-suppressive populations such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells. And the cold ones are the majority. Even in lung cancer, one of immunotherapy's best markets, the 2025 review is blunt: despite the transformative impact of checkpoint inhibitors, the majority of NSCLC patients experience resistance.

So picture the entire ICI industry, Keytruda and Opdivo and Tecentriq and Libtayo, standing at the mouth of a passage which leads into every cold-tumor market which they cannot currently reach, colorectal, breast, pancreatic, prostate, most of the solid-tumor landscape, and unable to get through. The field even knows exactly what the passage requires. The 2025 macrophage review states the strategy directly: because cold tumors are silenced largely by suppressive macrophages, oncology has begun to shift beyond T-cell approaches to target tumor-associated macrophages, a major pro-tumor population known to silence immune responses. Turn the Cold tumor Hot, repolarize the suppressive M2 macrophages to tumor killing M1 macrophages, and the passage opens. Whoever can do that reliably controls the chokepoint.

Why The Key Might Fit This Lock

The suppression which keeps a tumor Cold runs through specific machinery, and one of its master controls is the CCR5 receptor. This is where CytoDyn's bold claim earns its footing, because the mechanism is documented, not hoped for.

Blocking CCR5 in actual human colorectal liver metastases does the exact thing the field says is needed: it repolarizes macrophages from the immunosuppressive M2 state toward the anti-tumor M1 state. That is not a theory about a mouse. That is the passage-opening move, demonstrated in the tissue of the exact disease. And the newest reviews put CCR5 squarely at the center of the Cold-to-Hot strategy: the 2026 review of cytokine-driven tumor conversion notes that CCR5 antagonists potentiate the effects of checkpoint inhibitors and chemotherapy by reprogramming the tumor microenvironment to support anti-tumor immunity.

Now layer on what the CLOVER trial has actually shown, held exactly as what it is, early and unconfirmed and at the lower 350mg dose. Every one of the first patients measured showed a fall in circulating tumor DNA, with a median drop near seventy percent by week two. Every screened patient carried the target. And it did this with a safety profile the field can only envy, no dose-limiting toxicities, no drug-attributed serious adverse events across independent reviews. On the breast side, the retrospective work presented at ESMO by the CytoDyn and Creatv collaboration showed leronlimab driving PD-L1 upregulation on circulating tumor cells in the majority of patients, the precise molecular flag a checkpoint inhibitor requires to act. That is the Priming half of the thesis: leronlimab starts the engine in order that everyone else's expensive brake-release mechanism finally can do something.

The Honest Wall, Because The Bold Case Has To Clear It

Now the counterweight, and I put it at the center rather than in the footnotes, because this is exactly where a triumphant post would lie to you but I will not.

Targeting macrophages to open Cold tumors has a graveyard behind it. A brand-new 2026 review states the hard truth directly: several macrophage-directed approaches, including CCR2 and CCR5 antagonists and CSF1R inhibitors, advanced into clinical testing on compelling animal data, yet their activity in patients has generally been modest or inconsistent. The earlier macrophage-recruitment blockers, the anti-CCR2 agents carlumab and plozalizumab, did not demonstrate significant tumor responses in early trials.

Read that and hold it, because it cuts both ways and honesty demands both edges. On one edge: the mechanism being real in a dish or a liver biopsy has never been enough, this exact class of approach has repeatedly failed to translate, and leronlimab could join that list. That is the genuine risk, and anyone who tells you the biology guarantees the outcome is selling. On the other edge: those failures are why leronlimab's actual human signal matters so much. The field is littered with macrophage-directed drugs which looked good in mice but did nothing in people. Leronlimab is not showing a mouse signal. It is showing a hundred-percent ctDNA response in early human patients, PD-L1 induction in human tissue, and a clean safety record across a massive database > 1,700 patients. The wall is real, and leronlimab is one of the few in its class producing the kind of early human data that could clear it. The confirmation is what January is for.

Now The Leverage, And This Is The Part Worth Being Bold About

Here is where the chokepoint stops being biology and becomes arithmetic, and the arithmetic has gotten sharper in the last few months, not softer.

Consider whose ship is standing at the passage. Merck's Keytruda generated more than $29 billion in 2024, and its core patent expires in 2028. That is not a distant abstraction. It is the largest single revenue cliff in the history of the industry, and the pressure is now visible in Merck's own corporate structure: in February 2026, Merck announced the creation of a separate cancer business unit centered on Keytruda, whose key patents expire in 2028. They are reorganizing the company around this cliff. And it compounds: Keytruda was selected for Medicare price negotiation, so Merck faces biosimilar competition and government price-setting nearly simultaneously, forcing U.S. sales to peak in 2027 to 2028 and then fall sharply..

And Merck is not the only ship at the passage. Opdivo faces its own U.S. exclusivity loss in 2028, and Tecentriq faces biosimilar competition later in the decade. So it is not just one desperate buyer at the chokepoint. It is several, each watching their own franchise clock run down, each needing new Cold-tumor markets to replace what biosimilars are about to take.

Here is the move which turns the cliff into leverage, and it is the sharpest part of the whole argument. A new combination regimen carries its own patent. The patent strategists say so plainly: a checkpoint inhibitor paired into a new regimen can be protected by method-of-treatment patents covering the specific combination, dose, and schedule, wholly independent of the core molecule and which biosimilar manufacturers cannot circumvent. Read what that means. A leronlimab-plus-checkpoint combination for Cold tumors would be a new, separately-patented franchise, extending into markets the original molecule never reached, protected on a clock that runs past the biosimilar wave. The primer does not just add revenue. It manufactures a fresh patent estate in virgin territory at the exact moment the old estate collapses.

So let's put it all together. Several of the largest franchises in medicine are running out of patent life all, at the same time. The markets which could replace that revenue are Cold tumors, that their keys cannot open. The thing which does open Cold tumors is a primer that turns them Hot. And a primer paired with their ICI checkpoint inhibitor creates new, independent, biosimilar-proof patents in exactly those markets. The company who holds a proven primer would not be a supplicant asking a giant for a deal. It would be standing in the one and only passage several giants must transit through, at the precise moment when they can least afford to be turned away, holding the one thing none of them can quickly or easily build and which none can allow a rival to monopolize.

That is not sentiment. That is a seller's market with one seller and several buyer's clocks running out.

Where Prime And Pair Stops Being A Hope And Becomes A Convergence

I have called this "prime and pair" for a long time, and I want to state the bold version of what that phrase now means. It is not a clever idea I am hoping the field adopts. It is where the biology forces the entire field to converge, whether through leronlimab or through something else.

Look at the independent confirmations arriving from labs with no connection to CytoDyn. A 2024 study found that a completely unrelated drug repolarized suppressive macrophages toward the anti-tumor state with increased CCL5 chemokine secretion, restoring T-cell function and promoting a favorable anti-PD-1 response. A separate 2022 clinical study combining local therapy with a checkpoint inhibitor in patients who had already failed that checkpoint inhibitor produced responses, and the mechanism was macrophage polarization from the M2 to the M1 phenotype in the treated tumor. Different drugs, different labs, same convergence: Prime the microenvironment, repolarize the macrophages, and the ICI works where it could not before.

That is the tell. When independent groups using unrelated tools keep arriving at the same destination, the destination is real. The field converges on Prime-and-Pair because the biology of Cold tumors leaves no other road. Leronlimab's claim is not that it invented the road. It is that it may be the cleanest, safest, most proven vehicle currently traveling it. And the compromise everyone imagines, the eventual pairing of a primer with a checkpoint inhibitor, is not a compromise at all. It is the convergence that the entire field is being driven toward, and the only open question is who owns the Primer when the field arrives.

The One Thing That Is Not Yet Written

I have made the bold case, so I owe you the bold statement of its single point of failure, stated as plainly as everything else.

None of this is proof that leronlimab works. The chokepoint is real, the cliff is real, the convergence is real, the leverage is real, and every bit of it is inert until one number confirms that leronlimab actually does in patients what the mechanism says it should. The macrophage graveyard is real too, and it is exactly the fate a weak confirmation would seal. So the entire towering structure, the passage, the clocks, the seller's market, the new patent estate, rests on a single load-bearing event which has not yet happened: the confirmed response data, adjudicated, at ASCO GI in January. If that number is strong, none of the leverage spelled out above is speculation anymore. It is just arithmetic performed by companies with cliffs with no better option. If it is weak, there is no chokepoint, no leverage, and this entire post describes a passage which leronlimab could not, after all, open.

That is the honest shape of things. The boldest thing I can tell you is not that the outcome is certain. It is that the setup is enormous, the position is absolutely real, and the entire colossal question resolves to one single number at a known hour. The chokepoint definitely exists. Several giants are stranded at it on a closing clock. But we find out in January whether the small company in Vancouver is holding the way through.

I have never been more convinced that the stakes are as massive as they are. And I have never been more clear that conviction about the stakes is not the same as certainty about the result. Both of those are true at full volume. Most of you should know where I lean. January tells us which one governs.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology, public regulatory and patent history, and public corporate disclosures, not a prediction of clinical or commercial outcomes. No partnership has been announced; the identification of specific companies reflects public patent-cliff and competitive facts, not any claim of an existing negotiation. The mechanistic claims are supported by the cited peer-reviewed literature; several mechanisms are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The ESMO breast data is retrospective and hypothesis-generating. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

A study came out this week in Nature Microbiology, led by Nancy Haigwood and Jonah Sacha at OHSU, showing that a three-part regimen given to newborn macaques within three days of exposure prevented HIV from establishing itself. Antiretroviral therapy, broadly neutralizing antibodies, and leronlimab, the CCR5 blocker, together, Triple Therapy as we called it, did what none of the three did alone.

I want to walk through this carefully, because I have been writing about these exact threads for over a year now, and this is a chance to do something I find more useful than celebrating: go back to what I wrote back then, see which threads were real and which ones where we got ahead of the science, and mark clearly where this new result lands. The honest version is more compelling than the triumphant one, so let me give you that.

The Thread Which Turned Out To Be Real

A year ago, in a post called "Piecing It Together," I passed along something a reader had pushed me to include. I wrote: "it is not just Jonah Sacha and Scott Hansen, but it is also Nancy Haigwood who works on leronlimab's side... She's been working on this for a long time and should probably get a mention now and then." That was from "Piecing It Together," and I only included it because u/BuildGoodThings asked me to make sure she got credit.

Here is why that matters now. The study published this week is led by Nancy Haigwood. And the reporting makes clear it was her idea in the first place, she is the one who thought combining the existing therapies with leronlimab might work, and the paper is the demonstration that she was right. So the person I mentioned a year ago almost in passing, because BuildGoodThings insisted she deserved a mention, turns out to be the person whose insight this whole result rests on. That thread was real. I did not overclaim it. I just did not know then how central she would turn out to be.

The mechanism underneath it was also real, and I traced it correctly. Back in "Why Was VIR-1388 Terminated?", I quoted Scott Hansen describing what makes this approach possible. He said that Sacha "demonstrated that you can pharmacologically knock out CCR5 with leronlimab, essentially creating that Delta 32 phenotype", the same natural mutation that has produced the handful of true HIV cures through stem-cell transplant. That quote, from "Why Was VIR-1388 Terminated?", is the foundation the new paper stands on. Leronlimab chemically mimicking the Delta-32 state is exactly the lever the triple regimen pulls. That was true when Hansen said it, true when I wrote about it, and it is what the Nature Microbiology paper just put to work.

And the shape of the strategy was one I laid out in "Pushing Forward." I described the sequence the field would likely follow: prevent transmission from mother to child, then prevent the reservoir from forming in exposed newborns, then work toward clearing established infection. I wrote that "the next step would be the prevention of the development and establishment of HIV Reservoirs." That was from "Pushing Forward," and it is precisely what this paper reports: the regimen limited viral reservoir seeding in newborns. The step I named a year ago as the next one is the step that just got published.

So three threads I traced a year ago, Haigwood's centrality, the Delta-32 mimicry mechanism, and the reservoir-prevention strategy, all held. We own these honestly, but also got things wrong, and that is the next part.

I Did Not Trace This From The Sidelines. I Transcribed It.

Here is the part that makes the rest more than hindsight. A year ago, in a post called "Planet of the Apes," I sat down and transcribed Jonah Sacha presenting this exact study, slide by slide, at a conference in October 2024. The work that published in Nature Microbiology this week is the work I walked through then. So this is not me noticing a connection after the fact. It is me having laid out the actual data a full year before it hit the journal.

And the data I transcribed then is the data behind this week's headline. From "Planet of the Apes," relaying Sacha's own presentation: in the triple therapy group, after antiretroviral therapy was released, not a single animal rebounded. His words, which I quoted then, were that this was "in very stark contrast to the triple therapy group where not a single animal, 0 out of 8 rebounded." And then the harder test, the one that matters most: at week 60 they ran what Sacha called "the gold standard CD8 depletion," the assay designed to force a hidden reservoir out of hiding. In the control animals the virus came roaring back. In the triple therapy animals, nothing. I transcribed his conclusion directly: "cumulatively, this data suggests that the virus reservoir was indeed actually cleared in these animals."

But look closely at how careful Sacha himself was, because this is the part I most want to draw out. Even as he said the reservoir appeared cleared, he immediately added the honest caveat, which I also transcribed: "Difficult to prove in the negative, but all the data seems to support that." And on the mechanism, he was disarmingly plain: "As far as the mechanism of this, we actually don't know." The scientist presenting the most exciting HIV result in years stood up and said, in effect, this looks like clearance, I cannot prove a negative, and I do not know why it works. That is what real science sounds like, and I transcribed it faithfully a year ago.

Now notice what changed between that presentation and this week's paper, because it is the whole lesson of everything I have been writing lately. In 2024, the language around this work, including in my own post, leaned on the word "cleared." The peer-reviewed paper in 2026 uses the more careful framing: it "limits viral reservoir seeding." That is not a retreat. It is science tightening its own language as it moves from an exciting conference presentation to a peer-reviewed claim. "Appears cleared, cannot prove the negative" becomes "limits seeding," which is the more precise and more defensible statement of the same result. The data did not weaken. The wording got more honest. And that tightening, from the hopeful word to the exact one, is exactly the discipline I have been trying to practice in my own writing this year.

The Thread I Got Ahead Of, And Still Have To Mark

In that same "Pushing Forward" post, I wrote about the gene-therapy version of this work, the AAV approach, and I was honest even then that it had a problem. I wrote that "in a couple of the animals, anti-leronlimab anti-bodies developed and knocked out some of the leronlimab... So, Jonah Sacha still needs to do more work to get that part right." That was from "Pushing Forward," and I give myself partial credit: I did name the obstacle rather than paper over it.

But I also wrapped that honest observation in certainty it did not earn. I treated the eventual solution as a foregone conclusion, and elsewhere I let the HIV-cure story run toward inevitability. When the fuller data was published earlier this year, the anti-drug-antibody problem turned out stranger than a clean fix: in the gene-therapy work, the antibodies came back on their own, months later, through a mechanism the researchers still do not fully understand. I wrote about that in more detail recently, and the lesson stands here too. So when I read this week's triple-therapy result, I hold it against that same lesson: this is a real, published, peer-reviewed advance, and it is not the finish line.

What This Result Is, Held Exactly

Let me state precisely what the paper shows and what it does not, because that precision is the whole point.

It shows that in newborn macaques, treated within three days of exposure, the three-part combination prevented HIV from establishing a persistent reservoir, and did so far more effectively than any single component alone. Leronlimab's role is specific and, by the researchers' own account, central to the synergy: blocking CCR5 keeps the virus from entering cells, which Sacha described as keeping fuel away from the fire. That is genuinely important, and it is a legitimate advance in one of the hardest problems in medicine.

Here is what it is not. It is preclinical, in macaques, not humans. It is prevention of reservoir establishment in the earliest window, not eradication of established infection, the researchers are explicit that they only tested out to three days and do not yet know how far that window extends. Leronlimab is one of three components, not a standalone cure. And the path from this result to anything available to people runs through human clinical trials that have not happened yet, likely starting in newly exposed adults. The researchers say all of this plainly, and so will I.

There is also a disclosure worth stating myself rather than letting someone else surface it: OHSU has disclosed that Sacha and a co-author hold significant financial interests in CytoDyn. That is proper, it is how disclosed conflicts are supposed to work, and it does not diminish a peer-reviewed result in Nature Microbiology. But it is honest context, and part of holding a result correctly is naming the interests attached to it.

Why I Am Telling It This Way

I could have written this post as a victory lap, we called these threads a year ago, and look, they came true. Some of them did. But the version that is actually worth your time is the one that also shows you where I got ahead of myself, because that is what tells you how much to trust the parts that held.

The threads that were real, Haigwood's centrality, the Delta-32 mechanism, the reservoir-prevention sequence, and the data I transcribed straight from Sacha's own presentation, were real because they were grounded in what the scientists actually said and did, not in what I hoped for. The thread I got ahead of, the anti-drug-antibody problem being solved, went wrong exactly where I let hope outrun the data. That contrast is the most useful thing I can hand you, because it is the difference between tracing a real thread and spinning one.

This HIV work sits on its own track. It is not the oncology program, it does not touch the colorectal trial, and it is not what the near-term thesis rests on. It is long-dated, preclinical, one-of-three-components, and orthogonal to the data that actually moves the company this year. What it is, is real evidence that the mechanism we have been tracing for over a year, CCR5 blockade as a lever across the hardest diseases, keeps turning out to be more than enthusiasm. Haigwood was right. Sacha's Delta-32 mimicry works. The reservoir step got taken. And the honest limits are exactly the ones the scientists named.

A year ago I traced these threads and marked which were solid and which were still unproven. This week, one of the solid ones got published. I am still marking the unproven ones as unproven. That discipline is the only reason the solid ones are worth anything.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published, peer-reviewed research and public statements, not a prediction of clinical or commercial outcomes. The HIV research discussed is preclinical, conducted in non-human primates, tests a three-component regimen of which leronlimab is one part, and concerns prevention of reservoir establishment rather than cure of established infection; it does not establish safety or efficacy in humans. OHSU has disclosed that study authors hold significant financial interests in CytoDyn. This work is on the HIV research track and is separate from the company's oncology program; it is not a near-term catalyst. Mechanism and preclinical results are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.